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1        INTRODUCTION 
1.1      Overview of lung cancer  
1.1.1     Incidence and mortality of lung cancer 
Lung cancer was the most common cancer worldwide with nearly 1.8 million new cancer 
cases, and contribute 13% of the total number of new cancer cases diagnosed in 2012. In 
Germany, there are around 50,813 new cases of lung cancer, that’s 140 cases diagnosed every 
day. The age-standardized incidence for lung cancer in Germany is about 10.3% (Figure 1.1) 
[1, 2].  
 
Figure 1.1. Incidence of lung cancer worldwide and in Germany based on the data from 
GLOBOCAN project.  
 
Lung cancer is the leading cause of cancer-related death in men and the second leading cause 
in women worldwide [1, 3]. Lung cancer accounts for about 19.4% of all cancer deaths, with 
an estimated 1.6 million deaths in 2012 (1.1 million in men and 491,200 deaths in women). 
In Germany, there were around 43,420 lung cancer deaths in 2012, that’s 119 deaths every 
day. Lung cancer accounts for 20% of all cancer deaths in Germany (Figure 1.2) [1, 2]. 
According to the latest WHO data published in May 2014, lung cancers deaths in Germany 
reached 45,785, and the age-adjusted death rate is 27.78 per 100,000 of population. 
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Figure 1.2. Mortality of lung cancer worldwide and in Germany.  
 
1.1.2     Types of lung cancer 
Based on the way the cells look under a microscope, the vast majority of lung cancers are 
classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [4]. 
Although these two types of cancer share a common organ of origin and some molecular 
attributes, they have unique growth and spread patterns and represent distinct diseases. 
Therefore it is important to make a distinction between these two types of cancer for the 
purpose of cancer treatment [4, 5].  
SCLC is the most aggressive and rapidly growing tumor of all the types, and comprises 
around 15% of lung cancers. SCLCs can rapidly metastasize to other parts of the body and 
are most often diagnosed when they have spread extensively [6]. Approximately 85% of lung 
cancers are comprised of NSCLCs, which broadly includes squamous cell carcinoma (SqCC), 
adenocarcinoma (AdC), and large cell carcinoma subtypes. The AdC and SqCC subtypes 
represent about 85% of NSCLC cases. NSCLC is often insidious, producing no symptoms 
until the disease is well advanced [4, 7]. 
 
1.1.3     Lung cancer risk factors 
The evolution of lung cancer is a multistep process involving genetic, epigenetic, and 
environmental factor interactions. Exposure to risk factors may increase the risk of lung 
cancer. Exposure to tobacco smoke has long been recognized as the principal risk factor for 
development of lung cancer. More than 80% of lung cancers are attributable to active 
smoking. The lifetime risk of developing lung cancer in smokers is much higher than the one 
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in nonsmokers [8, 9]. Passive smoking also increases the risk of lung cancer and is a major 
contributor to indoor pollution. Although smoking is the major risk factor for lung cancer, not 
all patients with lung cancer have a smoking history. Global statistics estimate that 15% of 
men and 53% of women with lung cancer are never-smokers [10]. So there are other risk 
factors for lung cancer, which include radon, asbestos, polycyclic aromatic hydrocarbons, 
quartz dust, nickel dust and other pollutants [11, 12]. 
 
1.1.4     Lung cancer survival rate 
Most lung cancers are diagnosed at an advanced stage, where the prognosis is poor and 
therapeutic options are limited [7]. The survival rates for lung cancer vary depending on the 
cancer type and the stage of the disease. The overall 5-year survival rate for small cell lung 
cancer is only about 6%, while the one for non-small cell lung cancer is roughly 18%. The 5-
year survival for localized lung cancer is around 55%, while the 5-year survival rate for 
distant tumors (spread to other organs) is only 4 percent [13, 14]. Detection of lung cancer at 
an early stage leads to a better prognosis. However, only 16% of lung cancer cases are 
diagnosed at an early stage [15]. In order to develop more effective strategies in lung cancer 
diagnosing and treatment, the underlying molecular and cellular mechanisms of lung cancer 
remains to be explored.  
 
1.2      Cancer epigenetics  
1.2.1     Epigenetics  
As a relatively new scientific field, epigenetics has been intensely studied over the past two 
decades. Epigenetics represents a new frontier owing to its important role in regulation of 
normal biological processes and in development of human diseases, including cancer [16].  
Historically, the term ‘‘epigenetics’’ was originally coined by Conrad Waddington to 
describe heritable changes in a cellular phenotype without altering the DNA sequence [17].  
Nowadays, epigenetics can be defined as the study of any potentially stable and, ideally, 
heritable change in gene expression or cellular phenotype that occurs without alterations in 
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the DNA coding sequence [18, 19]. Epigenetics consists of heritable modifications including 
DNA methylation, histone modifications, nucleosome remodeling, and RNA-mediated 
targeting, all of which can influence overall chromatin structure [16]. Chromatin is the 
macromolecular complex of DNA and its intimately associated proteins, which provides the 
scaffold for the packaging of our entire genome. The fundamental repeating unit of chromatin 
is the nucleosome. The nucleosome contains 145–147 base pairs of DNA wrapped around a 
histone octamer, constructed from two copies of each of the core histones H2A, H2B, H3, 
and H4 [20]. The histone tails of all four core histones are subject to a variety of post-
translational modifications including methylation, acetylation, phosphorylation, 
ubiquitylation, all of which occur at the site of a specific amino acid, such as K4 and K9 on 
the histone H3 tail [21, 22]. For now, at least 4 different DNA modifications and at least 16 
distinct classes of histone modification have been described [18, 23]. These chemical 
modifications are dynamically laid down by “chromatin writers” and removed by “chromatin 
erasers” in a highly regulated manner. All of the “chromatin writers” and the “chromatin 
erasers” are chromatin-modifying enzymes [16]. These modifications can alter chromatin 
structure by altering non-covalent interactions within and between nucleosomes [18]. They 
also serve as docking sites for specialized proteins with unique domains that specifically 
recognize these modifications. These “chromatin readers” recruit additional chromatin 
modifiers and remodeling enzymes, which serve as the effectors of the modification [24]. All 
epigenetic processes work together to establish and maintain the global and local condensed 
or decondensed chromatin states that eventually determine gene expression. 
Epigenetic modifications play an important role in the regulation of critical cellular 
processes, such as transcription, DNA repair, and replication. Aberrant epigenetic events are 
intimately linked to human diseases, most notably cancer [25, 26]. 
 
1.2.2     Cancer epigenetics 
Cancer evolution at all stages is driven by both epigenetic abnormalities as well as genetic 
alterations [27]. In the last several years, the focus on the origin and progression of human 
cancers has shifted from genetic to epigenetic regulation, with particular attention to 
methylation and acetylation events that have profound effects on the eventual expression of 
oncogenes and the suppression of tumor suppressors [26, 28].   
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The cancer epigenome is characterized by global changes in DNA methylation and altered 
histone modification patterns [29]. For example, cancer cells show the global DNA 
hypomethylation and promoter-specific hypermethylation [30]. Disruption of the epigenetic 
machineries, either by mutation, deletion or the altered expression of any of their 
components, is known to provoke aberrant gene expression patterns that give rise to all 
typical cancer characteristics [31]. 
Aberrant epigenetic patterns associated with the development and progression of cancer have 
a potential clinical application. Since the aberrant DNA methylation events occurring in 
cancer cells have been extensively mapped, DNA methylation can be used as the biomarkers 
for cancer detection and prediction of therapy responses [32]. In contrast with the static 
alterations in DNA, epigenetic changes can potentially be reversed, making the epigenetic 
machineries involved in such processes promising therapeutic targets [29]. A few drugs 
targeting epigenetic changes have already been approved for cancer treatment. These 
epigenetic drugs include small molecules that target chromatin writers (DNA 
methyltransferase inhibitors), chromatin erasers (histone deacetylase inhibitors) and 
chromatin readers (histone acetylation reader inhibitors) [29, 33, 34].  
Epigenetic alterations, including DNA methylation, histone modifications, and non-coding 
RNA expression, have widely been reported in the literature to play a critical role in the 
genesis of lung cancer [35]. With the recent advances in the push towards personalized 
therapy, questions have been asked about the possible targeting of epigenetic events for 
personalized lung cancer therapy. Some progress has been made but a lot of work still need to 
be done. 
 
1.3      PHF20 
1.3.1     PHF20 in human cancers 
Plant homeodomainfinger protein 20 (PHF20, also termed glioma-expressed antigen 2, 
GLEA2) was originally identified as an antibody-reactive protein in patients suffering from 
glioblastoma [36]. In glioma patients, PHF20 elicit a frequent immune response, and 
autoantibodies against PHF20 led to a significant prolonged survival [37]. Interestingly, high 
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expression level of PHF20 correlated with lower survival in NSCLC patients [38]. In 
addition, PHF20 was also identified as a homolog of hepatocellular carcinoma associated 
antigen 58 (HCA58) [36].  Moreover, PHF20 was abundantly expressed in both advanced 
small-cell lung cancer and advanced adenocarcinoma [39]. Subsequently, abnormal 
expression of PHF20 in various cancers indicates that PHF20 might be tumor-associated 
factor and could play a role in cancer progression. However, little is known about the 
function of PHF20 in various cancers.  
 
1.3.2     Epigenetic role of PHF20 
PHF20 is a multidomain protein, which contains several domains including two Tudor 
domains, a plant homeodomain (PHD) finger and putative DNA-binding domains AT hook 
and C2H2-type zinc finger (Figure 1.3) [40]. Since Tudor domain and PHD finger domain 
have been identified as methylated lysine binding domains [41-44], PHF20 was considered as 
a histone code reader. Indeed, the first Tudor (Tudor1) domain doesn't bind dimethyl-lysine 
residues, due to an atypical and occluded aromatic cage [45]. Whereas the second Tudor 
(Tudor2) domain can bind to several histone methylation, including H4K20me2 and 
H3K79me2 [46]. Besides histone modification, the Tudor domain 2 also recognizes the 
methylated p65 and methylated p53 [40, 47]. PHF20 positively regulates NF-κB signaling 
through interacting with the dimethylated p65 at Lys221 (p65K221me2) through the Tudor2 
domain. The interaction of PHF20 with methylated p65 contributes to persistent p65 
phosphorylation by limiting the recruitment of phosphatase PP2A [47]. PHF20 directly binds 
to p53 dimethylated at K370 or K382 (p53K370me2 and p53K382me2) through its second 
Tudor (Tudor2) domain. Tudor2 forms a dimer capable of associating with both p53 
dimethyllysine marks simultaneously, thus greatly enhancing binding of PHF20 to p53. 
Interaction with PHF20 leads to the stabilization and activation of p53, because it blocks p53 
ubiquitination and upregulates p53 protein level in response to DNA damage [40]. PHF20 is 
a potent transcriptional activator by an epigenetic-based mechanism. 
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Figure 1.3 Schematic representation of PHF20. PHF20 contains two Tudor domains, a 
plant homeodomain (PHD) finger and putative DNA-binding domains AT hook and C2H2-
type zinc finger. 
PHF20 is a component of the MOF (male absent on the first)-NSL (non-specific lethal) lysine 
acetyltransferase complex responsible for acetylation of histone H4 and non-histone proteins 
and is implicated in transcriptional regulation and ataxia telangiectasia mutated (ATM)-
dependent DNA damage response [48-51]. The MOF-NSL complex shares the WD repeat 
domain 5 (WDR5) subunit with the H3K4-specific methyltransferase complex, MLL1, and 
stably associates with the MLL1 complex [49, 52, 53]. The joint recruitment and coordinated 
activities of both MOF and MLL1 complexes are required for optimal transcriptional 
activation of a set of genes, and a synergistic distribution of H3K4me and H4K16ac marks at 
promoters of these genes is evident [52, 53]. Genomic and biochemical studies reveal that 
MOF-NSL stimulates MLL1 activity, enhancing dimethylation of H3K4 in an acetylation-
dependent manner, and depletion of MOF or the NSL complex results in a reduction of 
H4K16 acetylation and H3K4 methylation [53]. 
The MOF-NSL complex is also capable of acetylating non-histone proteins, such as the 
transcription factor p53. Triggered by DNA damage, K120 acetylation in the DNA-binding 
domain of p53 stimulates expression of pro-apoptotic genes, promoting cell death [51, 54]. 
Additionally, p53 activity can be regulated by non-catalytic subunits of the MOF-NSL 
complex, OGT1 and PHF20. OGT1-catalyzed O-GlcNAcylation at S149 stabilizes p53 
through impeding T155 phosphorylation and ubiquitin-dependent proteolysis of p53 [55]. 
Recent in vivo and in vitro studies demonstrate that PHF20 transcriptionally regulates p53 in 
an Akt-dependent manner and promotes nuclear factor κB (NF-κB) transcriptional activity 
[47, 56]. Loss of PHF20 results in a decreased expression of genes with elevated H4K16ac 
levels at their promoters, further supporting the notion that PHF20 acts as a transcriptional 
regulator [57]. 
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1.4      Aims of this study 
Abundant expression of PHF20 is reported in various cancers [38, 39, 58]. PHF20 knockout 
mice die shortly after birth and display a variety of phenotypes within the skeletal and 
hematopoietic systems [57]. PHF20 deficiency halts conversion of somatic cells into induced 
pluripotent stem cells (iPSCs), revealing a requirement of this factor for cell reprogramming 
[59]. Despite the vital role of PHF20 in survival and carcinogenesis, the molecular 
mechanism by which PHF20 contributes to transcription and exerts carcinogenic activity 
remains unclear. 
In this study, we used lung cancer as a model to investigate the function of PHF20 in human 
cancer. We employ diverse approaches to elucidate how PHF20 affects cancer development 
at the cellular and molecular levels, including biochemistry, cell biology, next generation 
sequencing, and structure biology.  
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2        MATERIAL AND METHODS 
2.1      Materials  
2.1.1     Eukaryotic cell lines 
Human lung fibroblast cell lines WI38 and IMR90, and human lung cancer cell lines A549, 
H1299, H1355, H1792 and H1993 were used in this study. These cell lines were kindly given 
from Dr. John Heymach, Dr. Seyed Moghaddam and Dr. Min Gyu Lee in UT M.D. Anderson 
Cancer Center in United States. The human lung cells information is listed in Table 2.1. 
Human embryonic kidney cells HEK293T were used for virus packaging. The cell line was 
obtained from ATCC company (CRL-11268). 
Table 2.1 Lung cell lines information 
Cell line Tissue Histology Tumor Source Cell Type 
WI38 Lung Normal tissue NA Fibroblast 
IMR90 Lung Normal tissue NA Fibroblast 
A549 Lung NSCLC Primary Epithelial 
H1299 lung NSCLC Metastasis (lymph node) Epithelial 
H1355 lung NSCLC Metastasis (pleural effusion) Epithelial 
H1792 lung NSCLC Metastasis (pleural effusion) Epithelial 
H1993 lung NSCLC Metastasis (lymph node) Epithelial 
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2.1.2     Bacterial strains 
Rosetta-2 (DE3) competent cells (Catalog No: 71400) were purchased from Novagen, and 
were used for the expression of PHF20 WT and mutants. DH5α competent cells (Catalog No: 
18265017) were purchased from Invitrogen, and used for general cloning and subcloning.  
 
2.1.3     Plasmids constructs 
cDNA/Construct Vector Epitope tag Source 
pMD2.G  - Addgene 
pPAX2  - Addgene 
pENTR3C  - Invitrogen 
pGEX-6P-1  GST GE Healthcare 
pCDH-Blasticidin-GW  Flag-HA Dr. H Wen 
PHF20 pENTR3C - Dr. X Shi 
PHF20-Res pENTR3C - X Wang 
PHF20-Res pCDH-BT-GW Flag-HA X Wang 
PHF20 (E662K)-Res pENTR3C - X Wang 
PHF20 (E662K)-Res pCDH-BT-GW Flag-HA X Wang 
PHF20-PHD-L (aa 651-699) pGEX-6P-1 GST Dr. X Shi 
PHF20-PHD-L (E662K) pGEX-6P-1 GST X Wang 
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PHF20-PHD (aa 646-699) pTEV His Dr. TG Kutateladze 
PHF20-PHD (E662K) pTEV His Dr. TG Kutateladze 
PHF20-PHD (E662D) pTEV His Dr. TG Kutateladze 
PHF20-PHD (E662Y) pTEV His Dr. TG Kutateladze 
PHF20-PHD (F665K) pTEV His Dr. TG Kutateladze 
PHF20-PHD (C694S) pTEV His Dr. TG Kutateladze 
PHF20-PHD (W675A) pTEV His Dr. TG Kutateladze 
PHF20-PHD (R654H) pTEV His Dr. TG Kutateladze 
PHF20-PHD (F665V) pTEV His Dr. TG Kutateladze 
PHF20-PHD (M666I) pTEV His Dr. TG Kutateladze 
PHF20-PHD (C680F) pTEV His Dr. TG Kutateladze 
PHF20-PHD (P689L) pTEV His Dr. TG Kutateladze 
 
2.1.4     shRNA 
pLKO-scrambled shRNA negative control vector and pLKO-PHF20 shRNA constructs were 
purchased from Sigma. The PHF20-targeting shRNA sequences were 5′-
CCCGAGAAATACACCTGTTAT-3′ (shPHF20#1) and 5′-
ATTGTGCCACTGATGATAAAC-3′ (shPHF20#2).  
 
2.1.5     Antibodies 
Primary antibody Species Dilution for WB  Company  Catalog No. 
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anti-total H3 rabbit 1:5,000 Abcam ab1791 
anti-total H4 rabbit 1:5,000 Abcam ab7311 
anti-H4K16ac rabbit 1:1,000 Millipore 07-329 
anti-Flag mouse 1:5,000 Sigma F-1804 
anti-GST rabbit 1:5,000 Santa Cruz sc-459 
anti-tubulin mouse 1:5,000 Sigma T8328 
anti-β-actin mouse 1:5,000 Sigma A1978 
anti-PHF20 rabbit 1:1,000 Cell Signaling 3934S 
 
Secondary antibody Company  Catalog No. 
donkey-anti-rabbit IgG (H+L) Jackson ImmunoResearch 711-035-152 
donkey-anti-mouse IgG (H+L) Jackson ImmunoResearch 711-035-150 
donkey-anti-goat IgG (H+L) Jackson ImmunoResearch 711-035-147 
*All the secondary antibodies were diluted at 1:10,000 for Western blotting. 
 
2.1.6     Oligos for plasmids cloning and point mutagenesis 
All synthetic oligonucleotides were purchased from Sigma-Aldrich. Lyophilized 
oligonucleotides were dissolved in water. The sequences of both forward (For) and reverse 
(Rev) primers are given in the 5’ to 3’ direction. 
Oligo Sequence 
PHF20 PHD-BamHI-For GCCGGGATCCGATGGGGATGACCGC 
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PHF20 PHD-EcoRI-Rev GCCGGAATTCTTACCACTCCTTGTC 
PHF20-E662K-For TGTGAGGTCCAGGAGAAAAATGACTTCATG  
PHF20-E662K-Rev CATGAAGTCATTTTTCTCCTGGACCTCACA 
 
2.1.7     Common chemical reagents 
Chemical Name Catalog No. Manufacturer 
Agarose 15510-027 Sigma-Aldrich 
Bromophenol Blue 18030 Fluka 
Coomassie Brilliant Blue R-250 161-0400 Bio-Rad 
Ethylenediaminetetraacetic Acid  
Disodium Salt Dihydrate (EDTA) 
E5134 Sigma-Aldrich 
D-(+)-Glucose G5400 Sigma-Aldrich 
HEPES BP310 Fisher Scientific 
Magnesium Chloride Hexahydrate M2670 Sigma-Aldrich 
Magnesium Sulfate Heptahydrate M5921 Sigma-Aldrich 
Phenylmethanesulfonyl fluoride (PMSF) P7626 Sigma-Aldrich 
Potassium Chloride P3911 Sigma-Aldrich 
Sodium Bicarbonate S6297 Sigma-Aldrich 
Sodium Citrate Dihydrate S279 Fisher Scientific 
Sodium Dodecyl Sulfate (SDS) L4390 Sigma-Aldrich 
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Sodium Hydroxide S318 Fisher Scientific 
Sodium Phosphate Monobasic S8282 Sigma-Aldrich 
Sodium Sulfate S6547 Sigma-Aldrich 
Sucrose S0389 Sigma-Aldrich 
Zinc Chloride Z0152 Sigma-Aldrich 
Dimethyl Sulphoxide (DMSO) D8418 Sigma-Aldrich 
GRAM Staining Solution I (crystal violet) 6100 NEG Scientific Inc. 
10×Phosphate Buffered Saline (PBS) BP399 Fisher Scientific 
Triton X-100 T8787 Sigma-Aldrich 
Tween-20 BP337 Fisher Scientific 
Glycine BP381 Fisher Scientific 
Sodium Chloride BP35810 Fisher Scientific 
Tris base BP152 Fisher Scientific 
Ethyl Alcohol, 200 proof 61509 ACROS 
2-Mercaptoethanol M3148 Sigma-Aldrich 
RNAse Away 10328-011 Invitrogen 
Water (UltraPure, DNase- RNase- free) 10977-015 Invitrogen 
Hydrochloric Acid S93258 Fisher Scientific 
Formaldehyde 4018 PolySciences Corp. 
Glycerol G5516 Sigma-Aldrich 
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Methanol BP11054 Fisher Scientific 
Isopropanol BP2618 Fisher Scientific 
Glutathione, reduced form G4251 Sigma-Aldrich 
Streptavidin Sepharose 4B 17-5113-01 GE Healthcare 
UltraLink Immobulized Protein A/G 53133 Pierce 
Complete mini, EDTA-free, protease  
inhibitor cocktail 
12186500 Roche 
Albumin Standard 23210 Thermo Scientific 
Paraformaldehyde 19200 EMS 
DTT (1,4-dithio-DL-threitol) D9779 Sigma-Aldrich 
Glutaraldehyde G7526 Sigma-Aldrich 
Lysozyme L6876 Sigma-Aldrich 
Proteinase K (Fungal) 25530-015 Invitrogen 
 
2.1.8     Materials for PCR and quantitative real-time PCR 
Kit Name Catalog No. Manufacturer 
Taq DNA Polymerase 10342020 Invitrogen 
Power SYBR Green PCR Master Mix 4367659 ABI 
RNeasy Mini Kit 74104 Qiagen 
iScript cDNA Synthesis Kit 1708890 Bio-Rad 
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Table 2.2 Primers for qRT-PCR 
Gene Forward sequence Reverse sequence 
CCNA1 TCCAGAACTTCACCTCCATATCAG GATCCAACGTGCAGAAGCCTAT 
HMGB2 CCCGGACTCTTCCGTCAA TCCATCTCTCCGAACACTTCTTG 
G6PD TCCTGCGGGAAGAGCTTTT GATGAATATGTGTGTATCCGACTGATG 
MYB GGGCGTTTTTCTGACTTGGA GCAGTTCCGGCTCTGTACACT 
LIG1 CGAGGTCCTGAAACGCTTTG CTGCCCGTCATATTTGTATTCG 
E2F8 GGCACGGGCGACACAA CTTATTCTCCTCCCCGATGCT 
MNS1 GTCAACAGTCAAATCAGGAATCAAA GAAATTGCTTGCGCTGAACA 
GINS2 GCGGGACTTTCCTCACACA GGAGGTTCGTGCGGAGTTT 
E2F2 GCCTATGTGACTTACCAGGATATCC CCTTGACGGCAATCACTGTCT 
MYBL2 TGCCCCTTCAAACTCTTCCA CCTGGTTGAGCAAGCTGTTG 
KRT7 CCATGCCTGGTCCCAAGA TGCTTTATTGGAAGCTATTCTGACA 
TEX15 CAGCTGACTCCCTTGCATTG AAAGGCTGGGAATAAATGTCAAAT 
MKI67 CAGGAAAACAAGAGTCAGGTTCAGA GGACCTACGGCGTTGATCA 
CHAF1B GTCCCTCCAGCATTTTGCA GTTTCTCGGGCACCGTTCTA 
TK1 TTCCTACCTCTGGTGATGGTTTC TGCCACCCATCTTGGTGAA 
CCNE2 CCCAGCCAGACGGAATCC TCCTGGGTAGTTTTCCTCTTCTTG 
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2.1.9     Reagents for Western blotting 
Chemical Name Catalog No. Manufacturer 
40% Acrylamide/Bis solution.29:1 (3.3%) 161-0146 Bio-rad 
TEMED 1610801 Bio-rad 
Ammonium Persulfate (APS) BP179 Fisher Scientific 
Pierce supersignal western pico 
chemilunimescent substrate 
34080 Thermo Scientific 
Amersham ECL western blotting detection 
reagents 
RPN2106 GE Healthcare 
Amersham ECL Prime western blotting 
detection reagents 
RPN2236 GE Healthcare 
Millipore Immobilon western 
chemiluminescent substrate 
WBKLS0100 Millipore 
Gelcode Blue Stain Reagent 24592 Pierce 
PageRuler Plus Prestained 10-250kDa 
Protein Ladder 
PI26620 Thermo Scientific 
 
2.1.10     Materials for ChIP 
Chemical Name Catalog No. Manufacturer 
Glass beads, acid-washed, 212-300 um  G1277 Sigma-Aldrich 
Lithium Chloride L4408 Sigma-Aldrich 
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PIPES P1851 Sigma-Aldrich 
37% Formaldehyde BP531 Fisher Scientific 
 
Table 2.3 Primers for ChIP-PCR 
Primer For/Rev Location (bp) Sequence 
CCNA1-p 
Forward -350 TTAGCGGCTGTTGGGAGAAC 
Reverse -292 GATGGCCCCGGCTTTG 
CCNA1-c 
Forward +4620 TGCCCACCTGCCCTGAT 
Reverse +4675 TTAAGGTGAGCCATGCCAGAT 
HMGB2-p 
Forward -947 TGGCTCGGGAAGGAAAGC 
Reverse -1004 CCCCCAGTCTCCCGACTAAG 
HMGB2-c 
Forward +1348 CAAGGGTTGCGATACAGCAGTA 
Reverse +1275 GGACTATGGCACTGTGTGTGATG 
G6PD-p 
Forward -1037 TCTTCGGAAATGCCTCACATATAG 
Reverse -1101 CGAGCAAACAGGCATATGAAATC 
G6PD-c 
Forward +8837 GACAGGGTTTCCCCATGTTG 
Reverse +8774 GGCGGGCAGATCACTTGA 
MYB-p 
Forward -583 TGTAAACCTTGACGAAAATCCAATC 
Reverse -496 TCCTCCAGCTCCCACTCACT 
MYB-c Forward +25047 GCACTCTAGCCTGGGAGACAA 
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Reverse +25113 CCACGGCTGGCCTTAAAAA 
LIG1-p 
Forward -746 CACAGGTGAATACTGGTGACACTTC 
Reverse -808 TTATCCACGCTTCGCCTACA 
LIG1-c 
Forward +9994 CCCGGCGAAGGACAGAT 
Reverse +10092 CACTCATGTCTTCCTGGTCTGTAAA 
E2F8-p 
Forward +214 ACCTGTCAGTCCACCTCACG 
Reverse +152 AGCGGTGCTGACGAGTCC 
E2F8-c 
Forward +9532 AAACACTGCATGTTCTCACTCGTAA 
Reverse +9469 CCTCCCTGTGTCCATGTGTTC 
MNS1-p 
Forward +353 GCCAAAAAAGCTGGAAACCA 
Reverse +297 CGGAGGCTTCAGGTGCTATT 
MNS1-c 
Forward +27529 TCTGGCCAGGGCAGTCA 
Reverse +27432 ATACAATCATGTCATCTGCAAACAAG 
GINS2-p 
Forward +176 TCACCCCGATGAGGTAGATCTT 
Reverse +176 CGAGAAGGAGCTGGTTACCATT 
GINS2-c 
Forward +6897 TGGCACCATCACAGCTCACT 
Reverse +6838 GAGGCGGGAGGATTGCTT 
E2F2-p 
Forward -442 TGCATTGTTGCTTAGCTAGCACAT 
Reverse -503 TGGCCTTCATTTTAGCAGGAA 
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E2F2-c 
Forward +16079 TGCTAAGAAGACAAAAAGTGGAACA 
Reverse +16015 CGGCTAGACTGGCAGGATTC 
MYBL2-p 
Forward +1185 TGCAGTGGCGCGATCTT 
Reverse +1247 GGCAGGAGAATCGCTTGAAC 
MYBL2-c 
Forward +32788 GAGCCCATCGGTACAGATCTG 
Reverse +32851 GCTTCGGGAATTCCTCCAA 
KRT7-p 
Forward -1482 GGCACAATTCCAGGTCGAA 
Reverse -1424 CGGCTGTGGAGCATGTATGT 
KRT7-c 
Forward +8053 GTCCCTTTCCTTATCCCCTTTAAC 
Reverse +8113 GGCCCATTAGCAGTGTCTCAA 
TEX15-p 
Forward +529 CTTCTCCTCACTGTGGTTTTGGT 
Reverse +464 TCCTTCCCAATTTCTGTGTCAA 
TEX15-c 
Forward +10060 CAGGCACCCGCCACTATG 
Reverse +9992 GACCAACATGGTGAAACACTATCTCT 
MKI67-p 
Forward +719 CAATCCTAGAGCGCGTTTCTG 
Reverse +647 GCGGACGTTTTAGCTGAGAAAG 
MKI67-c 
Forward +15091 CGGCCATCCCCACTTTAAA 
Reverse +15028 CCATTCAATTCCCACTCTCAGTAA 
CHAF1B-p Forward +763 GTGAAATAGCCTGGCACAACAA 
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Reverse +822 CCGTCCCATGCTGGAAGT 
CHAF1B-c 
Forward +18384 TCTCAGAGGAGAATGTCTGCTCAT 
Reverse +18455 GGGCTATGTTGTCATCTCTATGCA 
TK1-p 
Forward +407 GAGAACATCGGCCCGAGAA 
Reverse +351 GCGGGCCCTCAAATGAC 
TK1-c 
Forward +9773 GCTCATTCCCAAGGTCTCATTATATT 
Reverse +9704 AGAAGTGTTTCGGATTTCAGGTTT 
CCNE2-p 
Forward -1647 GCCCAAGGTGACAGCATCA 
Reverse -1717 GCGTTAGAAATGGCAGAAAGTTTC 
CCNE2-c 
Forward +7887 GTGGTGGCAAGCACCTGTAA 
Reverse +7821 CCCAGGTTCAAGCGATTCTTC 
p: promoter, c: gene body 
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Figure 2.1 Schematic representation of ChIP-PCR primers location. The red line (-) 
represent the primer targeting gene promoter, while the blue line (-) represent the primers 
targeting gene body. 
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2.1.11     Reagents for bacterial culture 
Chemical Name Catalog No. Manufacturer 
Isopropyl b-D-1-thiogalactopyranoside (IPTG) I6758 Sigma-Aldrich 
Ampicillin sodium salt BP1760 Fisher Scientific 
Carbencillin sodium salt C1389 Sigma-Aldrich 
Chloramphenical C1919 Sigma-Aldrich 
Kanamycin sulfate K1377 Sigma-Aldrich 
Tryptone BP1421 Fisher Scientific 
Yeast Extract Powder BP1422 Fisher Scientific 
 
2.1.12     Reagents for mammalian cell culture 
Chemical Name Catalog No. Manufacturer 
RPMI 1640 10104CV Corning 
DMEM With 4.5g/L Glucose, Without L-
Glutamine and Sodium Pyruvate 
15017CM Corning 
Phosphate Buffered Saline (PBS), 1× 21040CV Corning 
Fetal Bovine Serum 35010CV Corning 
Penicillin-Streptomycin (10,000 U/mL) 15140122 Gibco 
Trypsin-EDTA (0.25%) 25200056 Gibco 
Trypan blue T8154  Sigma-Aldrich 
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DMSO (Dimethylsulphoxide) D2650  Sigma-Aldrich 
X-tremeGENE™ HP DNA Transfection 
Reagent 
06 366 546 001 Roche 
Polybrene 107689 Sigma-Aldrich 
Opti-MEM®I Reduced Serum medium 31985070 Gibco 
Puromycin Dihydrochloride A1113803 Gibco 
Blasticidin S HCl A1113903 Gibco 
DMEM powder 12800-017 Gibco 
 
 
2.2      Methods in molecular biology and biochemistry 
2.2.1     Solution stock preparation 
1. 1 M Tris-HCl Buffers    
pH Volume (L) Tris Base (g) HCl (mL)  
pH 7.0 2 242.2 150-155 
pH 7.5 2 242.2 120-125 
pH 8.0 2 242.2 80-85 
 *The concentration of HCl is 36.5-38.0%. 
2. EDTA 0.5 M (pH 8.0): Add 148 g of EDTA to 600 mL of H2O, use about 35 g of NaOH 
to adjust the pH value to 8.0. Then add H2O to 1000 mL.   
3. 10% SDS: Add 200 g of SDS into 2 L of H2O, heat to 68 ℃ for solubility.  
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4. NaCl solution (4 M): Add 467.5 g of NaCl into 2 L of H2O. Autoclave and store at room 
temperature (RT). 
5. NaOH solution (10 M): Add 200 g of NaOH into 0.5 L of H2O.  
6. NaAc (3 M): Add 204 g of NaAc·3H2O into 200 mL of H2O, adjust pH by glacial acetic 
acid (~60 mL) to pH 5.2. Then adjust to 100 mL. 
7. MgCl2 (1 M): Add 101.65 g of MgCl2·6H2O into 500 mL of H2O. Autoclave and store at 
room temperature. 
8. CaCl2 (1 M): Add 58.8 g of CaCl2·2H2O into 400 mL of H2O, then filter for sterilization 
and store at room temperature.  
9. MgSO4 (1 M): Add 123.3 g of MgSO4·7H2O into 500 mL of H2O. Autoclave and store at 
room temperature. 
10. ZnCl2 (0.1 M): Add 3.4 g of ZnCl2 into 250 mL of H2O. Store in -20oC. 
11. IPTG (1 M): Disolve 1 g of IPTG in 4.2 mL of H2O, then filter through 0.22 µm filters 
and aliquot 1 mL into Eppendorf tube. Store at -20oC. 
12. DTT (1 M): Disolve 5 g of DTT in 32.5 mL of 10 mM NaAc (pH 5.2) solution, then filter 
through 0.22 µm filters and aliquot 1 mL in Eppendorf tube. Store at -20oC. 
13. PMSF (100 mM, =17.4 mg/mL): Disolve 1.74 g of PMSF in 100mL of isoproponal. 
Aliquot and store at -20oC or RT.  
14. Carbencillin or Ampcillin (50 mg/mL) in water: Disolve 2.5 g of carbencillin or 
ampicillin in 50 mL of H2O. Aliquot and store at -20oC. 
15. Kanamycin (10 mg/mL) in water: Disolve 0.5 g of kanamycin in 50 mL of H2O. Aliquot 
and store at -20oC. 
16. Chloramphenicol (34 mg/mL) in ethanol:   Disolve 1.7 g of chloramphenicol in 50 mL of 
ethanol. 
17. Lysozyme 50 mg/mL: Disolve 2.5 g of lysozyme in 50 mL of H2O. 
 
2.2.2     Buffer preparation 
1. TAE DNA electrophoresis buffer (50×): 2 M Tris-HCl, 50 mM EDTA;      
Add 968 g of Tris base, 228.4 mL of glacial acetic acid and 400 mL of 0.5 M EDTA 8.0 
to 4 L of H2O. To make 1× TAE 20 L, add 400 mL of 50 × buffer into 19.6 L of ddH2O. 
2. SDS-PAGE gel solutions 
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 Vol (L) Tris Base (g) HCl (mL) 10% SDS (mL) 
4× Lower gel buffer 
    1.5 M Tris-HCl, pH 8.8, 
    0.4% SDS 
2 363.3 50-60  80 mL 
4× Upper gel buffer 
    0.5 M Tris-HCl, pH 6.8, 
    0.4% SDS 
2 121.1 70-80 80 mL 
*The concentration of HCl is 36.5-38.0%. 
 
3. 5 × SDS loading sample buffer 
 Stock solution Add volume 
250 mM Tris-HCl pH6.8 1 M 25 mL 
10% SDS  10 g 
30% Glycerol  30 mL 
5% β-mercapitalethanol   5 mL 
0.02% Bromophenol blue 1% 2 mL  
Then add H2O to 100 mL. 
4. 6× DNA loading sample buffer: 40% sucrose, 0.01-0.02% bromophenol blue 
Add 40 g of sucrose to 50 mL of H2O, add 2 mL 1% bromophenol blue solution, adjust to 
100 mL. 
5. SDS-PAGE electrophoresis running buffer (10 ×)  
Add 303 g of Tris Base, 1440 g of glycine and 100 g of SDS to 10 L of H2O.  
5.1 SDS-PAGE electrophoresis running buffer (1×): 25 mM Tris-HCl, 192 mM glycine, 
0.1% SDS 
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Add 1L of 10× SDS-PAGE running buffer into 9 L of H2O. 
5.2 Transfer buffer (1×): 25 mM Tris-HCl, 192 mM glycine, 0.1% SDS, 20% methanol 
Add 100 mL of 10× SDS-PAGE running buffer and 200 mL of methanol into 700 mL 
of H2O. 
6. TBS (10×): 
Add 876.6 g of NaCl and 121.1 g of Tris Base to 9 L of H2O, use about 55 mL of HCl to 
adjust the pH to 8.0. Then adjust the total volume to 10 L. 
6.1 TBS-T (1×): 150 mM NaCl, 10 mM Tris-HCl pH8.0 
Add 2 L of 10× TBS buffer, 200 mL of 10% Tween20 to 20 L of H2O.  
6.2 Blocking buffer: 5% nonfat milk in TBS-T 
Add 5 g of milk into 100 mL of 1× TBS-T buffer. 
7. Bacteria lysis buffer: 50 mM Tris-HCl 7.5, 150 mM NaCl, 0.05% NP-40 
Add 50 mL of 1 M Tris-HCl pH 7.5, 37.5 mL of 4 M NaCl and 5 mL of 10% NP-40 into 
1 L of H2O. 
8. RIPA buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% 
SDS 
Add 50 mL of 1 M Tris-HCl pH 7.5, 37.5 mL of 4 M NaCl, 4 mL of 0.5 M EDTA, 10 mL 
of NP-40 and 10 mL of 10% SDS in 1 L of H2O.  
9. Cell lysis buffer: 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.5% Triton X100, 10% 
glycerol, 1 mM DTT 
Add 50 mL of 1 M Tris-HCl pH 7.5, 62.5 mL of 4 M NaCl, 5 mL of Triton X-100, 1 mL 
of 1 M DTT and 100 mL glycerol in 1 L of H2O.  
 
2.2.3     Plasmid cloning by PCR 
Complementary DNA encoding full-length human PHF20 was cloned into pENTR3C vector. 
The PHF20 PHD finger region (aa651–699) was amplified by PCR and cloned from pENTR-
PHF20 into pENTR3C.  
2.2.3.1    Amplification of DNA fragments for cloning 
To amplify DNA sequences, the Taq DNA polymerase purchased from Invitrogen was used 
for PCR reaction. Add the following components to a sterile PCR tube sitting on ice:  
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Reagents Volume (µL) Final Con. 
10× PCR buffer (-Mg) 5 1× 
10 mM dNTP mixture 1 0.2 mM each 
50 mM MgCl2 1.5 1.5 nM 
PHF20 PHD-BamHI-For (10 µM) 2.5 0.5 µM 
PHF20 PHD-EcoRI-Rev (10 µM) 2.5 0.5 µM 
pENTR-PHF20 vector (50 ng/µL) 1 1ng/µL 
Taq DNA Polymerase (5 U/µL) 0.2 1 U/reaction 
Autoclaved distilled water  to 50 µL n/a 
Mix and briefly centrifuge the components.  
The PCR reaction was performed in a thermal cycler using the following program: 
Step  Temperature (°C) Time 
Initial Denaturation 94 3 min 
Denature 94 45 sec 
32 PCR Cycles Anneal 55 30 sec 
Extend 72 30 sec 
Final Extension 72 10 min 
Hold 4 indefinitely 
The amplification product was analyzed by agarose gel electrophoresis (2.2.3.2), purified 
(2.2.3.3) by QIAquick Gel Extraction Kit and and digested with restriction enzymes (2.2.3.4). 
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2.2.3.2    Agarose gel electrophoresis 
Agarose gel electrophoresis of DNA samples was performed for separating DNA by size for 
visualization and purification after PCR reactions or restriction enzyme digestions. According 
to their size, 0.8–2.0 % (w/v) agarose gels were prepared using TAE buffer containing 0.2 
µg/mL ethidium bromide (EtBr), which binds to DNA and makes the DNA visible under 
ultraviolet (UV) light. DNA samples were mixed with 6× DNA loading buffer and loaded on 
the gel. The gels were run in TAE buffer at a constant voltage of 100 V until the dye line is 
approximately 75-80% of the way down the gel. The DNA fragments can be visualized under 
UV light.  
2.2.3.3    DNA extraction from agarose gel 
After gel electrophoresis the DNA fragment of interest was excised from an agarose gel using 
a clean scalpel. The DNA was extracted using the QIAquick® Gel Extraction Kit according 
to the manufacturer’s instructions. After binding to the QIAquick membrane, the DNA was 
washed and finally eluted by adding 30 µL EB buffer.  
2.2.3.4    Digestion of DNA with restriction enzymes 
The purified DNA fragment and the recipient plasmid pENTR-3C were digested by 
restriction enzymes BamHI and EcoRI purchased from Fermentas. According to the 
manufacturer’s instruction, we used EcoRI buffer and 2-fold excess of BamHI to set up the 
digestion reaction system.  
For the DNA fragment digestion, the digestion reaction system is  
Reagents Volume (µL) 
nuclease-free water 5 
10× EcoRI Buffer 4 
BamHI (10 U/µL) 2 
EcoRI (10 U/µL) 1 
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Purified DNA fragment 28 
For the recipient plasmid digestion, the digestion reaction system is  
Reagents Volume (µL) 
nuclease-free water 11.5 
10× EcoRI Buffer 2 
BamHI (10 U/µL) 1 
EcoRI (10 U/µL) 0.5 
pRNTR-3C (200ng/µL) 5 
The mixture was incubated for 1 hour at 37 °C. 
2.2.3.5    Isolation of the DNA fragment and recipient vector by gel purification 
The digestion products were analyzed by agarose gel electrophoresis, then the DNA 
fragments and the linearized recipient vector were excised from an agarose gel using a clean 
scalpel. The DNA was extracted using the QIAquick® Gel Extraction Kit according to the 
manufacturer’s instructions.  
2.2.3.6    Ligation of DNA fragments 
The DNA Ligation Kit purchased from Takara was used for the ligation reaction. The 
reaction was performed according the manufacturer’s instructions. In brief, mix 5 µL of DNA 
fragment with 5 µL of linearized vector DNA in a PCR tube, then add 10 µL of Solution I 
and mix thoroughly. The mixture was incubated for 30 min at 16 °C. In parallel, a ligation of 
the recipient plasmid DNA without any insert was set up as a negative control.  
2.2.3.7    Transformation of plasmid DNA 
The ligation reaction mixture was used directly for transformation of DH5α competent cells. 
Add 10 µL of the ligation reaction into a vial of DH5α competent cells and mix gently. The 
vials were incubated on ice for 30 min, and heat-shocked for 90 seconds at 42°C without 
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shaking, followed by incubation on ice for 2 min. The bacteria were then cultured in 250 µL 
of LB medium at 37°C for 1 hour at 225 rpm in a shaking incubator. The cells were spread on 
the LB plate with kanamycin. 
2.2.3.8    Isolation of plasmid DNA 
Pick up 2 colonies and culture them overnight in 3 mL of LB medium containing 50 µg/mL 
kanamycin. The plasmid DNA was isolated using QIAprep Spin Miniprep Kit according the 
manufacturer’s instructions.  
The plasmids were analysed by restriction endonuclease digestion (2.2.3.4) and agarose gel 
electrophoresis (2.2.3.2) to confirm the presence of inserted cDNA. The BamHI and EcroRI 
restriction enzymes can be used. The plasmids containing inserted DNA were sequenced by 
Sanger Sequencing Method. 
 
2.2.4     Plasmid cloning using Gateway technique 
The full-length human PHF20 gene and PHF20 PHD finger (aa651–699) were subsequently 
cloned into destination vectors using the Gateway technique (Invitrogen). The Gateway 
Technology is a universal cloning method based on the site-specific recombination properties 
of bacteriophage lambda. The Gateway Technology provides a rapid and highly efficient way 
to move DNA sequences into multiple vector systems for functional analysis and protein 
expression.  
The sub-cloning reaction was performed using the Gateway LR Clonase II enzyme mix, 
which is a proprietary enzyme and buffer formulation containing the bacteriophage lambda 
recombination proteins Integrase and Excisionase, the E. coli-encoded protein Integration 
Host Factor (IHF). Gateway LR Clonase II enzyme mix catalyzes in vitro recombination 
between an entry clone and a destination vector to generate an expression clone.  
For the LR reaction, add the following components to a 1.5 mL Eppendorf tube at room 
temperature and mix:  
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Reagents Volume (µL) 
Entry clone (100 ng/µL) 1 µL  
Destination vector (150 ng/µL)  1 µL  
TE buffer, pH 8.0 to 8 µL  
Then add 2 µL of LR Clonase II enzyme mix to the reaction and mix well by vortexing 
briefly twice, followed by a brief spin. The mixture was incubated for 1 hour at 25°C. To 
terminate the reaction, 1 µL of the Proteinase K solution was added to each sample, followed 
by incubation at 37°C for 10 min.  
The LR reaction mixture was used directly for transformation of DH5α competent cells 
(2.2.3.7). 
 
2.2.5     PCR mutagenesis 
Point mutants of the PHF20 PHD finger were generated using the Stratagene QuikChange 
XL Site Directed Mutagenesis Kit and Pfu turbo DNA polymerase (Stratagene) according to 
the following protocol. Add the following components to a sterile PCR tube sitting on ice: 
Reagents Volume (µL) 
10× Pfu Turbo Reaction mix 2.5 
10 mM dNTP mixture 1 
DMSO 1.25 
PHF20-E662K-For (10 µM) 1 
PHF20-E662K-Rev (10 µM) 1 
pENTR-PHF20 vector (50 ng/µL) 1 
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Pfu turbo DNA Polymerase 1 
Autoclaved distilled water  16.25 
Mix and briefly centrifuge the components.  
The PCR reaction was performed in a thermal cycler using the following program: 
Step  Temperature (°C) Time 
Initial Denaturation 95 2 min 
Denature 95 20 sec 
19 PCR Cycles Anneal 55 30 sec 
Extend 68 14 min 
Final Extension 68 10 min 
Hold 4 indefinitely 
 
After PCR, transfer 20 µL of amplification product to a new tube and incubate each sample 
with 1µL of Dpn I for 1 hour at 37˚C. At the meantime, 5 µL of amplification product was 
used to analyze the quality by agarose gel electrophoresis (2.2.3.2). 5 µL of DpnI digested 
mixture was used directly for transformation of DH5α competent cells (2.2.3.7). All 
constructs were confirmed by DNA sequencing.  
 
2.2.6     Protein purification 
The PHF20 PHD finger construct (aa 651–699) was cloned into a pGEX-6P-1 expression 
vector using the Gateway technique. The WT and mutant proteins were expressed in E. coli 
Rosetta-2 (DE3) pLysS cells grown in Luria broth media supplemented with 150 µM ZnCl2, 
and then purified using Glutathione Sepharose 4B purchased from GE Healthcare Life 
Sciences. 
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2.2.6.1    Protein expression in Rosetta-2 cells 
1. 50 ng of pGEX-6P-PHF20-PHD(WT) or pGEX-6P-PHF20-PHD(E662K) plasmid was 
transformed into competent Rosetta 2 cells, which were plated on LB with 34 µg/mL 
chloramphenicol and 50 µg/mL ampicillin. The cells grown at 37 ˚C overnight.  
2. Pick up single colony to inoculate a starter culture of 12 mL LB/Cam/Amp in a 50 mL 
conical tube. The bacteria were then cultured at 37°C overnight in a shaking incubator. 
3. The next morning, transfer 10 mL overnight culture into a 250 mL flask with 100 mL LB 
medium containing with 50 µg/mL ampicillin and 150 µM ZnCl2, followed by incubation 
at 37˚C for ~1 hour in a shaking incubator. OD600 should be around 0.6-0.8, if lower 
than 0.6, check OD every 20 min. 
4. Once the OD600 >0.6, add 20 µL of 1M IPTG stock to a final concentration of 0.2 mM. 
The bacteria were then cultured at 20°C overnight in a shaking incubator. 
5. Harvest the bacteria by centrifugation for 15 min at 4000 rpm. Pour off supernatant and 
either begin lysis or store pellet at –80˚C. 
2.2.6.2    GST-tagged protein purification from bacteria 
Bug lysis buffer:          50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.05% (v/v) NP-40;  
                                      1 mM PMSF; protease inhibitors (added prior to use)  
Elution Buffer:            100 mM Tris-HCl, pH 8.0; 30 mM reduced glutathione 
1. Resuspend the bacterial pellet from a 100 mL culture in 10 mL chilled bug lysis buffer 
containing protease inhibitor and 1 mM PMSF. 
2. Add 100 µL of 50 mg/mL lysozyme solution to a final concentration of 0.5 mg/mL, leave 
on ice for 30-45 min, invert occasionally.  
3.  Sonicate with Branson Digital Sonifier at an output of 18% for 20 s. (1 s on, 1 s off), put 
back tube on ice. Repeat once.  
4. Centrifuge at 12000 rpm at 4˚C for 15 min. 
5. After spinning the lysed bacteria, transfer supernatant to 15 mL conical tube, and add 200 
µL of glutathione beads equilibrated with PBS.  
6. Rotate at 4˚C for 2-4 hours (can leave for overnight). 
7. Wash the beads twice with bug lysis buffer, and once with 100 mM Tris-HCl (pH 8.0). 
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8. Re-suspend the beads in 1 mL of 100 mM Tris-HCl (pH 8.0) and transfer to a 1.5 mL 
Eppendorf tube.  
9. Spin at 500 g at 4˚C for 5 min. Remove supernatant as much as possible. 
10. Add 350 µL of elution buffer, rotate at 4˚C for 4 hours or overnight. 
11. Spin at at 500 g at 4 ˚C for 5 min. Transfer 330 µL supernatant into a new 1.5 mL 
Eppendorf tube.  
12. Spin the supernatant again at 13000 rpm at 4 ˚C for 10 min, transfer 300 µL supernatant 
into a new tube. 
13. Determine protein concentration by Bio-Rad Bradford assay.  
14. The purified protein can be used freshly for up to a week. For long term storage, add 200 
µL of 50% glycerol to final concentration of 15-20%, make 30-50 µL aliquots depending 
on protein concentration and snap freeze with liquid nitrogen, store at -80 ˚C. 
 
2.2.7     Peptide microarray assay 
Binding buffer:          50 mM Tris-HCl, pH 7.5; 250 mM NaCl; 0.1% (v/v) NP-40; 
                                    1 mM PMSF; 20% (v/v) bovine serum albumin 
 Biotinylated histone peptides were printed in triplicate onto a streptavidin-coated slide 
(PolyAn) using a VersArray Compact Microarrayer (Bio-Rad). After a short blocking with 
biotin, the slides were incubated with the GST-PHF20-PHD in binding buffer overnight at 
4°C with gentle agitation. After being washed with the binding buffer, the slides were probed 
with an anti-GST primary antibody and then a fluorescein-conjugated secondary antibody 
and visualized using a GenePix 4000 scanner (Molecular Devices). 
 
2.2.8     Pull-down assay of biotin-labeled histone peptides 
1. Thaw the proteins GST-PHF20-PHD on ice. Spin at 13000 rpm for 10 min, and carefully 
take proteins from the top of the solution.  
2. Dilute proteins for binding: each binding requires 1 µg of GST-tagged protein in 300 µL 
of binding buffer.  Prepare an extra tube as input. 
3. Add 1 µg different biotinylated histone peptides (1 mg/mL) into each tube.  
4. Rotate at 4oC for 4 hours or overnight.  
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5. Prepare the Streptavidin Sepharose beads. Use 12-15 µL Streptavidin beads for each 
binding assay. Invert the bottle gently to mix the beads well before taking beads. Use a 
pipette to take sufficient slurry and transfer to a 15 mL Falcon tube, bring the volume to 
10 mL with cold binding buffer, spin the beads at 500 g for 3 min. Remove the 
supernatant and wash the beads at least two more times with binding buffer.  
6. Add 30 µL of 50% slurry into each tube. Rotate at 4˚C for 1 hour. 
7. Spin at at 500 g for 3 min, and carefully remove the supernatant. 
8. Wash the beads with 1 mL of binding buffer for 4 times. Rotate at 4 ˚C for 5 min for each 
wash. 
9. Resuspend beads in 60 µL of 1.5× SDS sample buffer. Boil it and ready for SDS-PAGE. 
For 10% input, take 30 µL of samples from the input tube, add 30 µL 2× SDS sample 
buffer and boil. Load 10 µL of boiled sample for each Western. 
 
2.2.9     Western blotting 
Proteins separated by SDS-PAGE (2.4.1) were immobilized on polyvinylidene fluoride 
(PVDF) membranes by the Western blot method, which allows the detection of proteins 
by specific antibodies. 
2.2.9.1     SDS-PAGE gel preparation 
Recipe of making SDS-PAGE 
 SDS-PAGE 7% 10% 12% 15% 
Running Gel 
20 mL (For 
4×1mm 
plates) 
4 × buffer pH 8.8 
(mL) 
5 5 5 5 
40% Acr-Bis (mL) 3.5 5 6 7.5 
ddH2O (mL) 11.5 10 9 7.5 
10% APS (µL) 100 100 100 100 
TEMED (µL) 20 20 20 20 
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 SDS-PAGE 4% 
Stacking Gel 
10 mL (For 6-
8 plates) 
4 × buffer pH 6.8 
(mL) 
2.5 
40% Acr-Bis (mL) 1 
ddH2O (mL) 6.5 
10% APS (µL) 100 
TEMED (µL) 20 
 
2.2.9.2    Loading and running the gel 
Load equal amounts of protein into the wells of the SDS-PAGE gel, along with molecular 
weight marker. Load 20–30 µg of total protein from cell lysate or 10–100 ng of purified 
protein. Run the gel for 1–2 hour at 100 V. 
2.2.9.3    Transfer 
1. During electrophoresis, cut the membrane to the dimensions of the gel. Pre-wet PVDF 
membrane in 100% methanol for few seconds, and equilibrate in transfer buffer for 10 
min before blotting. Completely saturate the filter paper by soaking in transfer buffer. 
2. After electrophoresis, equilibrate gel in 1× transfer buffer for 10 -15 min. 
3. Setup the transfer sandwich: 3 pre-soaked filter paper, gel, PVDF membrane, and 3 pre-
soaked filter papers. Roll a pipet or test tube over the surface of the filter paper to exclude 
all air bubbles. 
4. Set up the transfer condition: 15 V for 1 hour with SDS in transfer buffer. 
2.2.9.3    Blotting 
1. Following transfer, rinse the membrane with TBST buffer. Block the membrane for 1 
hour at room temperature using blocking buffer. 
2. Incubate the membrane with appropriate dilutions of primary antibody overnight 
incubation at 4°C in blocking buffer. 
3. Wash the membrane with TBST for three times, 10 min each. 
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4. Incubate the membrane with the recommended dilution of horseradish peroxidase (HRP) 
labeled secondary antibody in blocking buffer for 30 min at room temperature. 
5. Wash the membrane with TBST for three times, 10 min each. 
2.2.9.3    Detection 
For signal development, ECL western blotting detection reagents were used follow the kit 
manufacturer’s recommendations.  
1. Mix an equal volume of detection solution 1 with detection solution 2 allowing sufficient 
total volume to cover the membranes. The final volume required is 0.125 mL/cm2 
membrane.) 
2. Drain the excess wash buffer from the washed membranes and place them (Notes: protein 
side up) on a sheet of SaranWrap. 
3. Pipette the mixed detection reagent on to the membrane. Incubate for 1 min at room 
temperature. 
4. Drain off excess detection reagent by holding the membrane gently with forceps and 
touching the edge against a tissue. Place the blots protein side down on to a fresh piece of 
SaranWrap, wrap up the blots and gently smooth out any air bubbles. 
5. Place the wrapped blots, protein side up, in an X-ray film cassette. 
6. Exposure for 5-10 s, 30 s, 1 min, 5-10 min each. 
 
2.2.10  Quantitative real-time PCR and RNA-Seq analysis 
2.2.10.1 RNA extraction 
Total RNA was isolated from cells using the RNeasy Plus kit (QIAGEN) according to the 
manufacturer’s instruction. Adherent cells grown in a 10 cm cell-culture dish were directly 
lysed by adding 600 µL RLT buffer. Cell lysates were directly transferred into a QIAshredder 
spin column placed in a 2 mL collection tube, and centrifuged for 2 min at maximum speed. 
The homogenized lysate was transfered to a gDNA Eliminator spin column placed in a 2 mL 
collection tube, and centrifuged for 30 sec at maximum speed. After adding 600 µL 70 % 
(v/v) ethanol to the flow-through, the samples were loaded on RNeasy spin columns, the 
bound RNA was washed with RW1 buffer and RPE buffer. The RNA was eluted with 30 µL 
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RNase-free water. RNA concentration and purity was determined in a spectrometer, and 
RNA was stored at –80 °C. 
2.2.10.2 cDNA synthesis 
The complementary DNA (cDNA) was synthesized by reverse transcription PCR using the 
iScript cDNA Synthesis Kit (Bio-Rad). The reaction was setup by adding flowing reagents 
into a PCR tube. 
Reagent Volume (µL) 
5 × iScript Reaction mix 4 
iScript Reverse Transcriptase 1 
Nuclease-free water 15-x 
RNA template (1 µg) x 
Incubate the complete reaction mix in a thermal cycler using the following protocol.  
Step  Temperature (°C) Time 
Priming 25 5 min 
Reverse Transcription 46 20 min 
RT inactivation 95 1 min 
Hold 4 indefinitely 
After the reaction, the cDNA was diluted with sterile water to a volume of 100 µL and used 
as a template for quantitative real-time PCR.  
2.2.10.3 Quantitative real-time PCR 
Quantitative real-time RT-PCR was performed using the Power SYBR Green PCR Master 
Mix (Applied Biosystems). The reaction was setup by add the following components to a 96 
well real time PCR plate.  
44	
	
Reagent Volume (µL) 
Power SYBR® Green PCR Master Mix (2×) 5 
Forward Primer (0.25 µM) 1 
Reverse Primer (0.25 µM) 1 
Template cDNA (10 ng/µL) 2 
Water 1 
Quantitative real-time RT-PCR was performed on an ABI 7500-FAST Sequence Detection 
System using the following program: 
Step  Temperature (°C) Time 
Enzyme activation 95 10 min 
Denature 95 15 s 
40 PCR Cycles 
Anneal/ Extend 60 1 min 
Melt curve stage 
All experiments were performed in triplicates and gene expression was calculated after 
normalization to GAPDH cDNA levels using the comparative Ct (cycle threshold) method. 
The primer sequences used for RT-PCR are listed in Table 2.2. Experimental data are 
presented as means ± SD unless stated otherwise. Statistical significance was calculated by 
two-tailed unpaired t test on two experimental conditions with p < 0.05 considered 
statistically significant. 
2.2.10.4 RNA-Seq Analysis 
RNA-seq samples were sequenced using the Illumina Hiseq 2000. Three biological replicates 
were prepared for each condition. The sequencing reads were mapped to the human genome 
(hg19) by TopHat (version 2.0.10) [60]. The overall mapping rate was 95%–99%. The 
number of fragments in each known gene from RefSeq database [61] (downloaded from 
UCSC Genome Browser on June 2, 2014) was enumerated using htseq-count from HTSeq 
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package (version 0.6.0) (http://www-huber.embl.de/users/anders/HTSeq/). The differential 
expression between conditions was statistically assessed by R/Bioconductor package DESeq 
[62] (version 1.18.0). Genes with false discovery rate ≤ 0.05 and fold change ≥ 2 were called 
significant. Hierarchical clustering was performed by hclust function in R using their 
expression values estimated by DESeq. The expression values of each gene across samples 
were centered by median and scaled by SD before clustering. Euclidean distance and 
ward.D2 clustering method were used. The heatmap was plotted by heatmap.2 function in R. 
 
2.2.11  Cross-linking chromatin immunoprecipitation (X-ChIP) 
2.2.11.1 ChIP buffer preparation 
Cell Lysis Buffer:   5 mM PIPES pH 8.0; 85 mM KCl; 1% NP40; Add 
Protease Inhibitor and PMSF freshly. 
Nuclei Lysis buffer:   50 mM Tris-HCl pH 8.0; 10 mM EDTA; 1% SDS; Add 
Protease Inhibitor and PMSF freshly. 
Dilution buffer:   20 mM Tris-HCl pH 8.0; 150 mM NaCl; 1 mM EDTA; 
1% Trition X 100; 0.01% SDS; Add Protease Inhibitor 
and PMSF freshly 
Low salt wash buffer:   20 mM Tris-HCl pH 8.0; 150 mM NaCl; 2 mM EDTA; 
1% Trition X 100; 0.1% SDS 
High salt wash buffer:    20 mM Tris-HCl, pH 8.0; 500 mM NaCl; 2 mM EDTA; 
1% Triton X-100; 0.1% SDS 
LiCl wash buffer:   20 mM Tris-HCl, pH 8.0; 250 mM LiCl; 1 mM EDTA; 
1% NP40; 1% Na-deoxycholate 
TE buffer: 10 mM Tris-HCl 8.0; 1 mM EDTA  
ChIP Elution buffer: 50 mM NaHCO3; 1% SDS. (Make freshly!) 
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2.2.11.2 Procedure 
Cells were crosslinked with 1% formaldehyde for 10 min at room temperature, and the 
reaction was stopped with 125 mM glycine. Nuclei were isolated by resuspending the cells in 
cell lysis buffer for 20 min at 4 °C. The isolated nuclei were resuspended in nuclei lysis 
buffer and sonicated using a Bioruptor Sonicator (Diagenode). Samples were 
immunoprecipitated with 2–4 µg of the appropriate antibodies overnight at 4°C. 
Immunoprecipitates were washed twice in low salt wash buffer, twice in high salt wash 
buffer, once in LiCl wash buffer. Reverse crosslinking was performed by incubation at 67 ℃ 
for 12 hours in the presence of 0.3 M NaCl. The DNA was eluted and purified using a PCR 
purification kit (QIAGENe). 
 
 
 
2.3      Methods in cell biology 
2.3.1     Cell culture 
All cell lines were incubated at 37 °C in an atmosphere of 5 % CO2. 293T cells, normal lung 
cell line WI-38 and IMR90 were cultured in DMEM supplemented with 10% fetal bovine 
serum. H1792 and all lung cancer cell lines were cultured in RPMI 1640 supplemented with 
10% fetal bovine serum. Cells were grown in 10 cm cell culture dishes and routinely split 
every 2–3 days. For that purpose, cells were washed with PBS and incubated with 1 mL 
0.25% trypsin-EDTA for 1–3 min at 37 °C. Detached cells were washed off by adding 5 mL 
fresh complete medium, which stops the trypsin reaction, and seeded into a new dish at an 
appropriate dilution.  
 
2.3.2     Protein extraction and concentration measurement 
2.3.2.1    Cell Lysate Collection (For 10 cm dish of adherent cells) 
1. Place the cell culture dish on ice and wash the cells with cold PBS.  
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2. Suck the PBS, then add 1 mL of PBS-containing 1 mM PMSF. Scrap the cells off and 
transfer to 1.5 mL Eppendorf tubes. (Keep on ice from now on) 
3. Spin at 1000 g at 4°C for 3 min. 
4. Aspirate the supernatant. The cell pellets can be submitted to making cell lysate 
immediately or snap frozen in liquid nitrogen and stored at -80°C. 
5. Add x µL of cell lysis buffer (x=5 times the volume of cell pellets), resuspend the cell 
pellets by pipette up and down for several times. Briefly vortex for 5 s, then put on ice for 
20 min. 
6. Break the cells by sonication under the following condition: 15% output, 20 burst, 0.5 sec 
on, 0.5 sec off. 
7. Centrifuge at 12000 rpm for 10 min at 4°C, and supernatants were transferred into a fresh 
tube.  
2.3.2.1    Protein concentration measurement (Dc Protein Assay kit). 
According to the instruction, microplate assay protocol was used to measure the 
concentration. 
1. Preparation of working reagent. Add 20 µL of reagent S to each mL of reagent A that will 
be needed for the run. 
2. Prepare 3-5 dilutions of a protein standard containing from 0.2 mg/mL to about 1.5 
mg/mL protein. For best results, the standard should be prepared in the same buffer as the 
sample. 
3. Pipet 5 µL of standards and samples into a clean, dry microplate.  
4. Add 25 µL of working reagent A into each well. 
5. Add 200 µL reagent B into each well. Gently agitate the plate to mix the reagents.  
6. After 15 min, absorbance can be read at 750 nm. 
7. Based on the standard curve, calculate the protein concentration and adjust the 
concentration to 1mg/mL. Add 40 mL of 5× SDS loading buffer into 200 mL 1mg/mL 
cell lysate, boil for 10 min.   
 
2.3.3     Lenti-virus packaging 
The lentiviral systems were used to introduce stable knockdown or overexpression of PHF20 
gene in lung cancer cell line via short-hairpin RNA (shRNA) and complementary DNA 
(cDNA) expression.  
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2.3.3.1    Plate cells (Day 0) 
1. 24 hours before transfection, plate 293T cells in 10 cm cell culture dish. Cells should be 
40–70% confluent the next day prior to transfection.  
2. Incubate the cell cultures overnight at 37 °C in an atmosphere of 5 % CO2.  
2.3.3.2    Transfection (Day 1)  
1. Warm Opti-MEM reduced serum medium at 37℃ and FuGENE HD transfection reagent 
to room temperature. Vortex FuGENE HD transfection reagent briefly and gently before 
using. 
2. Place 500 µL of Opti-MEM reduced serum medium in a sterile 1.5 mL Eppendorf tube. 
Add 10 µg plasmid DNA (4 µg shRNA or cDNA: 4 µg pPAX:  2 µg PMD2.G) into the 
Opti-MEM medium, pipet gently to mix completely. 
3. Place 500 µL of Opti-MEM in another 1.5 mL Eppendorf tube, add 24 µL FuGENE HD 
transfection reagent. Vortex briefly or pipet gently to mix completely.   
4. Combine the plasmid solution and FuGENE HD transfection reagent solution together. 
Incubate at room temperature for 20–30 min to allow sufficient time for complex 
formation. Inverse gently a few times during incubation. 
5. Add the mix into a 10 cm dish cells in a drop-wide fashion, gently shake the dish to mix 
well.  
6. Incubate the cells at 37℃ and 5% CO2. 
2.3.3.3    Virus collection (Day 3) 
The virus was collected 2 days after transfection. The medium with virus was collected using 
10 mL syringe and filtered through 0.45 µm filters. The virus can be stored at 4℃ for short 
time use or split into into 2 mL aliquot which can be frozen at -80 ℃ for long-term storage. 
 
2.3.4   Virus transduction 
2.3.4.1    Plate cells (Day 0) 
H1792 cells were plated into 10 cm cell culture dishes 24 hours before virus infection. The 
cells should be around 40-70% confluent the next day. 
2.3.4.2    Virus infection (Day 1) 
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The next day, remove media and add 6 mL of new medium containing 64 µg polybrene. Add 
2 mL virus into each plate, and the final concentration of polybrene is 8 µg/mL. After 4-6 
hours, add 4 mL of complete medium into each plate. 
2.3.4.3    Medium replacement (Day 2) 
24 hours after infection, change medium or split if necessary. 
2.3.4.4    Selection with drugs (Day 3) 
To select the infected cells, the proper drugs were added into the medium. For H1792 cells, 
the proper concentration of puromycin is 1.5 µg/mL, while the proper concentration of 
blasticidin is 10 µg/mL.  
2.3.4.5    Stable cell line maintenance 
Change medium every 1-2 days or split cells when necessary. In 2-3 days all non-transduced 
cells should have been killed and the stable cell lines can be maintained in culture for at least 
2 months.  
 
2.3.5     Colony formation assay 
Colony formation assay is an in vitro cell survival assay based on the ability of a single cell 
to grow into a colony [63]. As described previously, H1792 cells treated with shRNAs were 
seeded in six-well plates (800 cells/well) and grown in RPMI 1640 plus 10% FBS at 37°C for 
14 days. Cells were fixed, stained with 0.005% crystal violet blue, and photographed. Colony 
numbers were counted using ImageJ software with size cut off of 75 µm. Results were 
quantitated from at least three independent replicates. 
 
2.3.6     Soft agar assay  
1.2% agarose: weigh 1.2 g agarose and add 100 mL of ddH2O, autoclave and mix well to 
make a uniform gel solution after autoclaving. This can be stored at room temperature for a 
couple of months. 
2× RPMI 1640 medium: make from RPMI 1640 powder (Gibco Cat. No. 51800019) 
according to the manufacturer’s instruction. One bag of powder is for making 1L of 1× RPMI 
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1640, so only use it to make 500 mL of 2× RPMI 1640. Double all the supplements you need 
to make them 2×.  
2.3.6.1    Preparation of base agarose layer 
All steps must be done sterilely and use cell culture grade water 
1. Melt 1.2% agarose in microwave. Let it cool down in a 42°C water bath, and allow at 
least 30 min to equilibrate the temperature.  
2. Using conical tubes, warm 2× complete RPMI1640 containing 20% FBS and 2× all the 
other supplements to 42°C in water bath. Allow at least 30 min for temperature to 
equilibrate. 
3. Quickly but thoroughly mix equal volumes of the two solutions to give 0.6% agarose + 
1× RPMI 1640 + 10% FBS. 
4. Quickly add 1.5 mL of mixture from step 3 to each well of 6-well plate, swirl a bit on the 
bench to allow the gel solution to completely cover the culture surface. Put the plates 
aside for 5 min to allow agarose to solidify.  
 
2.3.6.2    Preparation of top agarose    
1. Melt 1.2% agarose in a microwave. Mix well and aliquot 2.5 mL into each 15 mL 
conical tubes and put them in a 42°C water bath. Allow about 30 min for temperature to 
equilibrate. 
2. Put an aliquot of complete 2× RPMI 1640 medium in the 42°C water bath.  
3. Trypsinize H1792 cells, collect dis-attached cells and spin down, resuspend pellet in 
suitable volume of medium to make the cell density fall in the range of 5× 105-1× 106 
cells/mL. Count cells to determine the exact cell density. 
4. Calculate the volume of cell suspension that will yield the number of cells you want to 
seed in one well. For each cell density, seed three wells as replica. Calculate the volume 
of every reagent as in Table 2.4 to make the top agarose-cell mixture layer for three 
wells. 
5. Mix the cell suspension prepared in step 4 with 1 mL of pre-warmed 2× complete RPMI 
1640 medium and 1 mL of 1.2% agarose quickly and thoroughly. Then add 1 mL of this 
mixture to each well and let it spread evenly on top of the base agarose. 
6. Allow the top agarose-cell layer to solidify for 30 min at RT.  
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7. Add 1-1.5 mL of regular medium to the well, and put them back in the 37°C incubator. 
8. Change medium every 4 days. Culture them until colonies can be seen with naked eye. 
9. Colony numbers can be scored under light microscope, adjust the depth of the field by 
changing the focus to count 8-10 three-dimensional fields. 
 
 
 
Table 2.4 Recipe of top agarose 
No. of cells be seeded in each well  2×10^4 5×10^4 1×10^5 
Vol. of cell suspension       
Vol. of cells for triplicate       
Vol. of 1×DMEM for triplicate       
Vol. of 2×DMEM for triplicate 1 mL 1 mL 1 mL 
Vol. of 1.2% agarose for triplicate 1 mL 1 mL 1 mL 
Vol. of cells for triplicate=3.5× vol. of cell suspension 
Vol. of 1×DMEM for triplicate= (0.4-vol of cells) ×3.5 
 
 
2.4        Methods in structural biology 
2.4.1     X-ray crystallography 
PHF20 PHD C674S (aa 651–699) was concentrated to ∼16 mg/mL in 20 mM Tris-HCl (pH 
7.5), supplemented with 130 mM NaCl and 5 mM dithiothreitol. The protein solution was 
incubated overnight with the H3K4me2 peptide (aa1–12) in a 1:1.5 molar ratio before 
crystallization. Crystals were grown using the sitting-drop diffusion method at 4°C by mixing 
600 nL protein-peptide solution with 600 nL well solution composed of 0.1 M bis-tris 
propanol (pH 6.5), 2.55 M ammonium sulfate titrated with 6 µL/1 mL 1 N HCl. Although the 
histone peptide was present, PHF20 PHD C674S was crystallized in an apo-state. 
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Cryoprotected crystals (soaked in mother liquor with ∼30% glycerol) were picked and 
plunged into liquid nitrogen. X-ray diffraction data were collected from a single crystal at 
National Synchrotron Light Source X25 (BNL) beamline. The protein structure was solved 
using Single-wavelength Anomalous Dispersion method with Zn anomalous signal. Datasets 
were processed with HKL2000 and CCP4. Refinement was carried out using Phenix [64], 
and the model was built with Coot [65].  
 
2.4.2     NMR titration experiments 
The 1H,15N HSQC spectra of 0.1 mM uniformly 15N-labeled WT or mutant PHD finger 
domain of PHF20 in PBS (pH 6.7), 5 mM dithiothreitol buffer or Tudor2 in 25 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 5 mM dithiothreitol buffer were collected at 298K on Varian 
INOVA 600- and 500-MHz spectrometers. The binding was characterized by monitoring 
chemical shift changes as 12-mer histone tail peptides (synthesized by the University of 
Colorado Denver Peptide Core Facility) or p53 (aa 377–387) was added stepwise. The Kds 
were determined using a nonlinear least-squares analysis in KaleidaGraph and the equation 
 
where [L] is concentration of the peptide, [P] is concentration of the protein, Δδ is the 
observed chemical shift change, and Δδmax is the normalized chemical shift change at 
saturation. Normalized chemical shift changes were calculated using the equation 
Δδ = , where Δδ is the change in chemical shift in parts per million 
(ppm). 
 
2.4.3     NMR structure determination 
NMR experiments were recorded at 25°C using a 700-MHz Bruker Avance III spectrometer 
equipped with a cryoprobe. The NMR data were processed and analyzed using NMRPipe and 
NMRViewJ. Protein samples were in 25 mM sodium phosphate buffer (pH 7.0), 1.5 mM 
NaN3, 0.3 mM sodium 4,4-dimethyl-4-silapentane-1-sulphonate, 10% D2O, and 90% H2O. 
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The 11-residue C-terminally amidated H3K4me2 peptide [ART(Kme2)QTARKST] was 
purchased from GenScript and purified by reverse-phase high-performance liquid 
chromatography (HPLC) using a Jupiter 5u C18 300A preparative column (Phenomenex). 
For structure determination, PHF20 PHD and H3K4me2 peptide were at concentrations of 
1.5 and 6 mM, respectively. A series of standard NMR experiments was recorded for 
backbone and side-chain resonance assignments including 2D correlation spectroscopy 
(COSY), 1H,15N and 1H,13C HSQC, and 3D HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, 
HBHA(CO)NH, CCH-TOCSY, 15N NOESY-HSQC, and 13C NOESY-HSQC. 15N NOESY-
HSQC and 13C NOESY-HSQC optimized for aliphatic and aromatic spectral regions were 
recorded with a mixing time of 120 ms to generate distance restraints. 3D 13C,15N-
filtered, 13C/15N-edited NOESY experiments were recorded with a 120-ms mixing time to 
unambiguously identify intermolecular nuclear Overhauser enhancement (NOEs). 
For structure calculations, interproton distances were derived from 15N NOESY-HSQC, 13C 
NOESY-HSQC, and 13C,15N-filtered, 13C/15N-edited NOESY experiments and categorized 
into five distance ranges with upper limits of 2.8, 3.5, 4.5, 5.5, and 7.5 Å; the 7.5 Å is to 
account for possible spin diffusion in very weak NOE signals. Hydrogen bonds were 
determined from deuterium exchange experiments and given upper limits of 3.2 Å (for N-O) 
and 2.2 Å (for HN-O). For all distance restraints, a lower limit of 1.8 Å was used. Dihedral 
angles φ and ψ were derived from TALOS and CSI analysis. Two hundred structures of free 
PHF20 were initially calculated using the simulated annealing protocol of CYANA. Twenty 
of these structures with the lowest energies were then used to analyze for violations and 
obtain additional SANE-assisted NOE assignments for PHF20. Several iterations of CYANA 
and SANE were carried out until distance and angle violations fell below 0.3 Å and 5°, 
respectively. Next, the above procedure was repeated but introducing the H3K4me2 peptide 
in the calculations. Two hundred structures of the PHF20-H3K4me2 complex were 
calculated, and 100 of those with the lowest energies were refined using AMBER. In 
AMBER refinement, the structures were subjected to 30 ps 30,000 steps of simulated 
annealing using a generalized Born solvent model. The system was first heated to 1,000 K in 
the first 8 ps and remained at 1,000 K for 2 ps. It was then annealed and cooled to 0 K for the 
next 20 ps. Force constants were set as follows: 20 kcal mol−1 Å2 for NOE-derived distance 
restraints, 40 kcal mol−1 Å2 for hydrogen bond restraints, 70 kcal mol−1 rad−2 for dihedral 
angle restraints, 100 kcal mol−1rad−2 for chirality restraints, and 150 kcal mol−1rad−2 for 
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omega angle restraints. At the end of the refinement, 20 structures with the lowest AMBER 
energies and violations were selected for final structure statistics. 
 
2.4.4     Fluorescence spectroscopy 
Spectra were recorded at room temperature on a Fluoromax-3 spectrofluorometer (HORIBA). 
The samples containing the PHF20 PHD finger domain in PBS (pH 6.8), 10 mM DTT buffer, 
and progressively increasing concentrations of histone peptide were excited at 280 nm. 
Emission spectra were recorded over a range of wavelengths between 310 and 405 nm with a 
0.5-nm step size and a 1-s integration time and averaged over three scans. The Kd values 
were determined using a nonlinear least-squares analysis and the equation 
 
where [L] is the concentration of the histone peptide, [P] is the concentration of the protein, 
ΔI is the observed change of signal intensity, and ΔImax is the difference in signal intensity of 
the free and bound states of the protein. The Kd value was averaged over three separate 
experiments, with error calculated as the SD between the runs. 
 
 
2.5        Online databases and analysis 
2.5.1     GLOBOCAN project and online analysis 
GLOBOCAN is a project of the International Agency for Research on Cancer, and provides 
contemporary estimates of the incidence, mortality and prevalence from major types of 
cancer at national level. These estimates are based on the best available data in each country 
and on information publically available on the Internet.  In order to obtain the incidence and 
mortality of lung cancer worldwide and in Germany, the online analysis tools 
(http://globocan.iarc.fr/Pages/online.aspx) of GLOBOCAN project 
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(http://globocan.iarc.fr/Default.aspx) were used. Pie charts were used to present the incidence 
and mortality of lung cancer by population.  
 
2.5.2     TCGA database and cBioPortal for Cancer Genomics 
The Cancer Genome Atlas (TCGA) project is supervised by the National Cancer Institute's 
Center for Cancer Genomics and the National Human Genome Research Institute funded by 
the US government. TCGA program applies high-throughput genome analysis techniques to 
generate, analyze, and made available genomic sequence, gene expression, gene methylation, 
and copy number variation (CNV) data. The aim is to improve our ability to diagnose, treat, 
and prevent cancer through a better understanding of the genetic basis of cancer. TCGA 
(https://cancergenome.nih.gov/) is one of the largest and most commonly used public 
resource to date. 
The cBioPortal for Cancer Genomics was originally developed at Memorial Sloan Kettering 
Cancer Center (MSK). The public cBioPortal site (http://cbioportal.org) is hosted by the 
Center for Molecular Oncology at MSK. The cBioPortal software enables interactive, 
exploratory analysis of large-scale cancer genomics data sets including TCGA database. 
To investigate PHF20 gene alterations in human cancers, the cBioportal software was used to 
analyze PHF20 gene mutation and CNV mainly within TCGA database. Briefly, on the 
cBioPortal site (http://cbioportal.org), TCGA studies were selected and “Mutation and CNV” 
was chosen for “Data Type Priority”, then enter PHF20 gene and submit query. The result 
was downloaded and used directly. 
 
2.5.3     Kaplan-Meier plotter analysis 
Kaplan-Meier (KM) Plotter (http://kmplot.com/analysis/) is a database that integrates gene 
expression data and clinical data. Till 3rd December 2017, the KM Plotter is capable to assess 
the effect of 54,675 genes on survival using 10,461 cancer samples, which include 5,143 
breast, 1,816 ovarian, 2,437 lung and 1,065 gastric cancer.  
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To determine the correlation between expression level of PHF20 and the overall survival 
(OS) of lung cancer patients, KM plotter analysis was carried out. Briefly, on the KM Plotter 
site (http://kmplot.com/analysis/), Click “Start KM Plotter for lung cancer” from mRNA 
project, and goes into lung cancer specific website. Set the parameters as follows, 
Affy id/Gene symbol: 1569906_s_at (Input PHF20 and select 1569906_s_at) 
Split patients by: median 
Survival: OS 
Set other parameters as defaults. 
Then draw Kaplan-Meier Plot and download the result directly. To determine the correlation 
with different types of lung cancer, set the parameters as before, and set Histology as 
adenocarcinoma or squamous cell carcinoma. 
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3        RESULTS 
3.1      PHF20 is required for cancer cell growth and survival 
3.1.1     PHF20 gene is amplified in human cancers including lung cancer  
To establish the biological function of PHF20, we first analyzed the TCGA database and 
assessed PHF20 gene alterations in human cancers. PHF20 is amplified in a variety of 
human malignancies, including colorectal, uterine, cervical, bladder, and lung cancers (Figure 
3.1).  
 
Figure 3.1 PHF20 is amplified in human cancers. The gene alterations frequency data is 
obtained from the TCGA database. 
In order to investigate whether PHF20 expression level correlates with patient survival, we 
utilized Kaplan-Meier survival plot to analyze the correlation between PHF20 expression and 
lung cancer. It was shown that high expression of PHF20 was significantly correlated with 
lower survival rate (P=1.1e-05, hazard ratio (HR) =1.33 with 95% confidence interval 1.17–
1.51) in lung cancer patients (Figure 3.2). Moreover, this correlation only existed in lung 
adenocarcinoma patients (P=1.2e-06, Figure 3.3 left), but not in lung squamous carcinoma 
(P=0.46, Figure 3.3 right). 
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Figure 3.2 Kaplan–Meier analysis of survival of lung cancer patients with low (black) or 
high (red) PHF20 expression. The number of surviving patients at 0-, 50-, 100-, 150- and 
200- month time points is indicated below the graph.  
 
 
Figure 3.3 Kaplan–Meier analysis of survival of lung adenocarcinoma patients (left) and 
lung squamous carcinoma (right) with low (black) or high (red) PHF20 expression. The 
number of surviving patients at 0-, 50-, 100-, 150- and 200- month time points is indicated 
below the graph. 
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3.1.2     PHF20 is overexpressed in lung adenocarcinoma cell lines 
In order to study the biological function of PHF20 in lung adenocarcinoma, we firstly 
determine the PHF20 gene expression and protein levels across a number of lung 
adenocarcinoma cell lines together with normal lung fibroblast cell lines. Our qRT-PCR and 
immunoblotting results showed that, compared with the normal lung fibroblast cells (WI-38 
and IMR90), PHF20 is overexpressed in all lung cancer cell lines that we examined at 
protein levels (Figure 3.4B). 
 
Figure 3.4 PHF20 expression is amplified in lung adenocarcinoma cell lines. qRT-PCR 
(A) and western blot analysis (B) of PHF20 gene expression and protein levels, respectively, 
in the indicated lung adenocarcinoma cell lines and control immortalized normal cells. 
GAPDH expression was used as internal control in (A), and actin was used as a loading 
control in (B). Error bars represent SEM of three replicates. 
 
3.1.3     Depletion of PHF20 inhibits cell proliferation and division in H1792 
cells  
To further evaluate the contribution of the up-regulation of PHF20 to the oncogenesis of lung 
adenocarcinoma, we knocked down PHF20 gene expression in H1792 lung adenocarcinoma 
cells using lentiviral PHF20-specific short hairpins (shRNAs) constructs. qRT-PCR and 
immunoblotting analyses were performed to assess the efficiency of shRNAs. Compared with 
control non-targeting shRNA (shNT), both shPHF20 #1 and shPHF20 #2 effectively knocked 
down endogenous PHF20 expression at mRNA level and protein level (Figure 3.5).  
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Figure 3.5 shPHF20 effectively knocked down endogenous PHF20 expression.  (A) qRT-
PCR analysis of PHF20 knockdown in H1792 cells. **p<0.01 in comparison with control; 
(B) Western blot analysis of PHF20 knockdown in H1792 cells. 
Interestingly, we found that the cells notably grow slower after PHF20 depletion.  To 
confirm the effect of PHF20 on cell growth, we performed cell proliferation assay, which 
showed that depletion of PHF20 markedly inhibited the cell growth of H1792 cells.  (Figure 
3.6 left). Similarly, knockdown of PHF20 expression obviously reduce cell growth in H1299 
(Figure 3.6 middle) and H1993 cells (Figure 3.6 right). 
Figure 3.6 Cell proliferation assays of the control and PHF20 KD H1792 cells (left), 
H1299 cells (middle) and H1993 cells (right). Live cells were counted over a 6-day time 
course. Error bars represent SEM of six replicates. 
To determine the effect of PHF20 on the cancer cell division, we performed the clonogenic 
assay. The control and PHF20 KD H1792 cells were plated at low density, and grow under 
normal culture condition. The cell colonies were fixed, stained, and counted two weeks later. 
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As shown in Figure 3.7A, the PHF20 KD H1792 cells formed less colonies compared with 
control cells. The colonies were counted and summarized in Figure 3.7B. 
Figure 3.7 Colony formation assays of the control and PHF20 KD H1792 cells. 
Representative crystal-violet-stained cells are shown in (A), and quantification is shown in 
(B). Error bars represent SEM of six replicates. ∗∗p < 0.01. 
 
3.1.4     Depletion of PHF20 inhibits colony formation in H1792 cells  
The ability to exhibit anchorage-independent growth of cancer cells in vitro has been 
considered as a key aspect of the tumor phenotype, particularly with respect to metastatic 
potential [66]. To further demonstrate the effect of PHF20 on tumor cell aggressiveness, we 
performed the soft agar colony formation assay in control and PHF20 depleted H1792 cells. 
As expected, compared with well-developed colonies observed in control cells, PHF20-
depleted cell colonies were fewer and relatively smaller in size (Figure 3.8).  
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Figure 3.8 Soft agar assays in the control and PHF20 KD H1792 cells. 
PHF20 is upregulated in several human cancers including lung cancer, indicating PHF20 is a 
candidate oncogene. Depletion of PHF20 significantly inhibited cell growth and colony 
formation. These data suggest that PHF20 has an oncogenic role in lung 
adenocarcinoma, promoting cancer cell growth and survival. 
 
3.2      PHF20 regulates the expression of genes involved in cancer 
and cell cycle 
3.2.1     RNA-seq in PHF20-depleted cells 
PHF20 is a component of the MOF-NSL lysine acetyltransferase complex and is implicated 
in transcriptional regulation [48, 49, 51]. In order to study the molecular mechanism under 
which PHF20 promotes cell growth, firstly we utilized RNA sequencing (RNA-seq) analysis 
to identify PHF20-regulated genes genome-wide. We knocked down PHF20 gene expression 
and performed RNA-seq analysis in H1792 lung adenocarcinoma cells.  PHF20 was reported 
as a transcriptional coactivator [67]; however, we found similar numbers of genes were 
down- (942 genes) and upregulated (895 genes) in PHF20 KD cells compared with the 
control cells. Ingenuity Pathway Analysis (IPA) revealed that the most affected genes are 
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implicated in vital biological processes, including cell cycle and DNA replication, 
recombination and repair, cellular movement, and cell proliferation and death. Notably, both 
down- and up-regulated genes are enriched for cancer, organismal injury, and connective 
tissue diseases (Figure 3.9). 
Figure 3.9 Heatmap and IPA of gene expression profiles in the control (shNT) and 
PHF20 KD (shPHF20) H1792 cells. The green and red colors indicate down- and 
upregulation, respectively. The right panel shows the IPA of the down- and upregulated 
genes in PHF20 KD cells. The top five hits in each category are listed. 
 
3.2.2     Validation of RNA-seq results via qRT-PCR 
In order to validate the RNA-seq results, we first randomly selected 16 downregulated genes 
in PHF20 KD cells and performed qPCR analysis. All the genes tested showed considerable 
reductions of gene expression upon PHF20 knockdown by two independent shRNAs (Figure 
64	
	
3.10). Our RNA-seq results can explain how PHF20 affect cancer cell growth and cell 
proliferation through regulating gene transcription. 
 
Figure 3.10 qRT-PCR analysis of gene expression in control (shNT) and PHF20 KD 
(shPHF20) cells. 
 
3.3      PHF20 recognizes histone H3K4me2 via its PHD finger 
PHF20 has a modular architecture consisting of tandem Tudor domains (Tudor1 and Tudor2), 
an AT-hook, a C2H2-type zinc finger, and a plant homeodomain (PHD) finger (Figure 1.3) 
[40]. Biochemical and structural studies have shown that Tudor2 associates with 
dimethyllysine substrates [40, 45, 46], particularly with p53K370me2 and p53K382me2 [40]; 
however, biological activities of other domains, including the PHD finger, remain unknown. 
Because a set of PHD finger-containing proteins was found to bind histone sequences [41, 
42, 68-70], we tested the PHF20 PHD finger in histone peptide microarrays, pull-down 
assays and nuclear magnetic resonance (NMR).  
 
3.3.1     PHF20 PHD finger binds to H3K4me2 in histone peptide microarray 
assay 
We used histone peptide microarray contains unmodified histone H3 and H4 peptides or 
histone peptides bearing single methylation marks to screen the PHF20 PHD finger. 
Unexpectedly, we found that the PHF20 PHD finger strongly binds to H3K4me2 peptide but 
does not recognize either H3K4me3 or unmodified H3 that were previously reported as 
ligands for PHD fingers. PHF20 PHD finger domain specifically recognized methylated H3 
but not methylated H4 or methylated H2A (Figure 3.11). 
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Figure 3.11 Histone peptide array probed with GST-PHF20 PHD. 
 
3.3.2     PHF20 PHD finger specifically recognizes H3K4me2 in histone 
peptides pull-down assay 
To confirm the specificity of the PHF20 PHD finger toward H3K4me2, we performed pull-
down assays. The glutathione S-transferase (GST) fusion PHD finger was incubated with 
biotinylated unmodified histone H3 and H4 peptides or histone peptides containing single 
methylation marks. The histone-bound PHD finger was captured using streptavidin 
Sepharose beads and detected by western blot analysis. The result was consistent with the 
peptides microarray assay, the PHF20 PHD finger specifically binds to H3K4me2 peptide 
(Figure 3.12).   
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Figure 3.12 Western blot analysis of histone peptide pull-downs with GST-PHF20 PHD 
and the indicated biotinylated peptides. 
 
3.3.3     HSQC titration experiments indicate direct binding between PHF20 
PHD finger and H3K4me2 
To compare binding of the PHF20 PHD finger to the methylated H3K4 species in more 
detail, we carried out 1H,15N heteronuclear single quantum coherence (HSQC) titration 
experiments. Gradual addition of the H3K4me2 peptide to the 15N-labeled PHD finger caused 
large chemical shift perturbations (CSPs) in the protein, indicating direct binding 
(Figure 3.13, left). However, interaction with H3K4me3 was considerably weaker judging by 
small CSPs observed upon titration with this peptide (Figure 3.13, right).  
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Figure 3.13 Superimposed 1H,15N HSQC spectra of the PHF20 PHD finger collected 
upon titration with the indicated peptides. Spectra are color coded according to the 
protein: peptide molar ratio shown on the left. 
 
3.3.4     The PHF20 PHD finger binds to the H3K4me2 peptide with highest 
affinity in fluorescence spectroscopy assay 
Quantitative measurements of binding affinities using fluorescence spectroscopy further 
corroborated these results. The dissociation constant (Kd) for the interaction of the PHF20 
PHD finger with H3K4me2 was found to be 3.6 µM; however, interaction with H3K4me3, 
H3K4me1, and H3K4me0 was ∼6-, ∼14-, and ∼20-fold, respectively, weaker (Figure 3.14).  
 
Figure 3.14 (A) Binding affinities of WT PHF20 PHD for the indicated histone peptides 
measured by tryptophan fluorescence. (B) Representative binding curves used to determine 
the Kd values. 
Collectively, our data derived from four orthogonal biochemical approaches demonstrate that 
the PHF20 PHD finger exhibits high selectivity for H3K4me2, representing an example 
of the native PHD finger capable of reading the dimethylated species. 
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3.4      Molecular basis for the recognition of H3K4me2 
3.4.1     Solution structure of the PHD finger in complex with the H3K4me2 
peptide 
To determine the mechanism underlying recognition of H3K4me2, we obtained a 1.25-Å 
resolution crystal structure of the PHF20 PHD finger in the apo-state and the solution 
structure of the PHD finger in complex with the H3K4me2 peptide (Figure 3.15; Tables 3.1 
and 3.2). The NMR ensemble shows a canonical fold of the PHD finger, consisting of a short 
double-stranded antiparallel β sheet, two α-helical turns, and several loops connecting two 
zinc-binding clusters (Figure 3.15A). The histone H3K4me2 peptide is bound in an extended 
conformation in a branched negatively charged channel (Figure 3.15B). The peptide is 
aligned with β1 of the PHD finger, allowing for the formation of a three-stranded antiparallel 
β sheet (Figure 3.15A). 
 
Figure 3.15 Solution structure of the PHD finger in complex with the H3K4me2 peptide. 
(A) The PHD finger is depicted in the ribbon diagram, and the H3K4me2 peptide is shown in 
a stick model. The histone peptide residues and the residues of the PHF20 PHD finger 
involved in the interaction are labeled. (B) The electrostatic surface potential of the PHF20 
PHD finger is shown using blue and red colors for positive and negative charges, 
respectively. 
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Table 3.1 X-ray crystallographic data collection and refinement statistics.  
 PHF20 PHD 
Data collection  
Space group  
Cell dimensions 
P61 
a, b, c (Å) 46.74, 46.74, 50.93 
    α, β, γ  (°) 90, 90, 120 
Resolution (Å)  31.69-1.25 (1.29-1.25) * 
Rsym or Rmerge 5.8 (24.3) 
I / σI 7.4 (3.1) 
Completeness (%) 99.7 (97.8) 
Redundancy 1.9 (1.8) 
 
Refinement  
Resolution (Å) 31.69-1.25 
No. reflections 17326 
Rwork / Rfree 11.8/14.4 
No. atoms 510 
Protein 425 
Ligand/ion 14 
Water 71 
B-factors 13.6 
Protein 11.5 
Ligand/ion 35.2 
Water 21.8 
R.m.s. deviations  
Bond lengths (Å) 0.012 
Bond angles (°) 1.47 
*Values in parentheses are for highest-resolution shell. 
Table 3.2 NMR restraints and refinement statistics.   
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NMR distance and dihedral restraints PHF20  PHD–H3K4me2 
Distance restraints  
Total NOE 2294 
Intra-residue 545 
Inter-residue 1635 
Sequential (|i-j|=1) 515 
Medium-range  (|i-j|<5) 380 
Long-range(|i-j|>4) 740 
Intermolecular 114 
Hydrogen bonds 10 
Total dihedral angle restraints 86 
φ 44 
ψ 42 
  
Structure  statistics  
Violations(mean ± s.d)  
Distance constraints (Å) 0.08±0.06 
Dihedral angle constraints (°) 0.60±0.71 
Max. dihedral angle violation (°) 4.10 
Max. distance restraint violation (Å) 0.27 
Deviations from idealized geometry  
Bond lengths (Å) 0.0116±0.0001 
Bond angles (°) 2.62±0.02 
Impropers (°) 0.38±0.02 
Average pairwise r.m.s. deviation (Å) a  
Heavy 0.73±0.11 
Backbone 0.19±0.05 
a  Calculated from residues 651-699 of PHF20 and residues 1-5 of H3K4me2. 
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3.4.2     The binding between PHF20 PHD finger and H3K4me2 is 
accompanied by a large conformational change 
The first six residues of the H3K4me2 peptide, from A1 to T6, are in direct contact with the 
PHF20 PHD finger. The methyl group of A1 lies in a deep cavity lined with Y692 of the 
protein, whereas the amino terminus of A1 is located within a short distance to the backbone 
carbonyl oxygen atoms of P689 and E690. The guanidino group of Arg2 is in close proximity 
to the carboxyl group of E651 (Figure 3.15A). An overlay of the structures of the PHF20 
PHD finger in complex with the H3K4me2 peptide and in the apo-state reveals that the 
binding is accompanied by a large conformational change in the protein N-terminal loop 
where E651 resides (Figure 3.16). Upon complex formation, E651 swings toward the core of 
the PHD finger, most likely forming electrostatic and/or hydrogen bonding contacts with the 
positively charged R2 of the H3K4me2 peptide and thereby stabilizing the complex. 
 
Figure 3.16 An overlay of the NMR structure of the PHF20 PHD-H3K4me2 complex 
(wheat-green) with the crystal structure of the apo-state of PHF20 PHD (gray). 
 
3.4.3     The preference of PHF20 for the dimethyllysine mark is independent 
on the size of the methyllysine binding pocket. 
The fully extended side chain of K4me2 occupies an elongated groove, framed by V653, 
E662, M666, and W675. The side chains of E662 and W675, which are oriented 
perpendicularly to the protein surface, create the walls of the groove, whereas V653 and 
M666 line the bottom (Figure 3.15). To test the idea that the specificity of the PHF20 PHD 
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finger for H3K4me2 over H3K4me3 is due to a smaller size of the methyllysine binding site, 
we superimposed the K4me2-binding groove of PHF20 with the K4me3-binding pocket of 
the inhibitor of growth, member 2 (ING2) PHD finger [71] and computed solvent-accessible 
surface areas (Figure 3.17). We found that the K4me2-binding groove in PHF20 is slightly 
larger (∼273 Å) compared with the K4me3-binding pocket of ING2 (∼200 Å). These data 
imply that the size of the binding pocket is not a factor responsible for the preference of 
PHF20 for the dimethyllysine mark. 
 
Figure 3.17 Superimposed H3K4me2 (green)-binding site of PHF20 PHD (wheat) and 
H3K4me3 (light blue)-binding site of ING2 PHD (light blue) (PDB: 2G6Q) are shown. 
 
3.4.4     The glutamate residue of the K4me2-binding pocket determines the 
specificity of the PHF20 PHD finger 
The current predominant view that helps explain specificity of some methyllysine-
recognizing readers, such as Tudor and MBT domains, for mono- or dimethylated lysine 
sequences is the presence of a negatively charged aspartate or glutamate residue in the 
methyllysine binding pocket [24, 72, 73]. However, this view is not pertinent to PHD fingers 
because the PHD fingers of MLL5, TAF3, and Pygo have an aspartate residue (D128, D877, 
and D352, respectively) in the methyllysine-binding cage (Figures 3.18A and 3.18B), yet 
MLL5 and TAF3 prefer H3K4me3 over H3K4me2 by ∼5- to 10-fold [74-76], and Pygo binds 
both marks with the same affinity of 2.4–2.5 µM [77]. Because the PHF20 PHD finger 
contains the glutamate residue (E662) instead, we tested whether the longer glutamic side 
chain accounts for the specificity toward H3K4me2. We generated the E662D mutant of the 
PHD finger and examined its binding to H3K4me2 and H3K4me3 peptides by NMR and 
tryptophan fluorescence (Figures 3.18C and 3.18D). We found that the E662D mutant of 
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PHF20-PHD interacts with both peptides equally well, exhibiting 3.6 µM affinity for 
H3K4me2 and 3.7 µM affinity for H3K4me3. These results suggest that the shorter aspartic 
side chain in PHF20-PHD E662D does not discriminate between the tri- and dimethylation 
states of H3K4, and a longer glutamic side chain is indeed necessary to select for H3K4me2. 
 
Figure 3.18 Molecular basis for the selectivity toward dimethyllysine. (A) Alignment of 
the PHD finger sequences: absolutely, moderately, and weakly conserved residues are 
colored light blue, orange, and yellow, respectively. The H3K4me3-binding site residues of 
MLL5 and TAF3, as well as the H3K4me2-binding site residues of PHF20 and the Y17E 
mutant of BPTF, are circled. (B) A close view of the Kme-binding sites of the PHD fingers of 
MLL5, TAF3, and the Y17E mutant of BPTF. The histone peptide is yellow. PDB codes 
are 4L58, 2K17, and 2RI7. (C) Binding affinities of mutated PHF20 PHD for the indicated 
histone peptides as measured by tryptophan fluorescence. NB, no binding. (D) Overlays 
of 1H,15N HSQC spectra of the mutated PHF20 PHD fingers collected upon titration with the 
indicated peptides.  
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Although we cannot validate hydrogen bond formation in NMR-derived structures, a short 
distance between the dimethylammonium group of H3K4 and the carboxylic group of E662 
suggests that these groups interact through hydrogen bonding and ionic contacts. Unlike the 
trimethylammonium group of H3K4 in the MLL5 and TAF3 complexes that is located 
roughly at equal distance between the aromatic tryptophan residue and the aspartic acid (∼4.7 
and ∼4.0 Å, respectively, in the MLL5 complex) (Figure 3.18B), the position of the 
dimethylammonium group of H3K4 in the PHF20 complex is shifted toward E662 [74, 78, 
79]. A similar shift toward the glutamate residue is observed in the crystal structure of the 
H3K4me2-bound Y17E mutant of the PHD finger of bromodomain PHD finger transcription 
factor (BPTF) [73]. This mutant prefers H3K4me2 as opposed to wild-type (WT) BPTF that 
selects for H3K4me3 [73] and, in support of the binding mode of PHF20, the distances 
between K4me2 and W32 and E17 in the Y17E BPTF complex are 4.5 and 2.7 Å, 
respectively (Figure 3.18B). These structural and biochemical analyses demonstrate that the 
glutamate residue present in the K4me2-binding pocket is the major determinant of the low-
methylation state specificity of the PHF20 PHD finger. 
 
3.5      Mutations in the PHD finger decrease binding to H3K4me2 
3.5.1     Cancer related PHD finger mutants decrease binding to H3K4me2 
A number of cancer-associated mutations and deletions have been identified in PHF20, 
several of which occur in the PHD finger (Catalogue of Somatic Mutations in Cancer 
[COSMIC]; Figures 3.19A and 3.19B). To determine whether the cancer-relevant mutations 
affect binding of the PHD finger to H3K4me2, we produced R654H, F665V, M666I, and 
P689L mutants of PHF20 found in stomach, breast, kidney, and lung cancers, and we tested 
the corresponding 15N-labeled proteins by NMR (Figure 3.19C). We found that binding of 
R654H, F665V, and P689L to H3K4me2, compared with WT, was decreased ∼ 8-, ∼ 9-, and 
∼ 17-fold, respectively, whereas M666I was unstructured. Mapping the cancer-relevant 
mutations on the structure of the PHD-H3K4me2 complex revealed that some of the mutated 
residues can be essential for proper folding of the domain (such as the hydrophobic core 
residue M666 or a zinc-coordinating residue C680), or they make contacts with the histone 
peptide (such as F665 and P689). Overall, these data demonstrate that some cancer-relevant 
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mutants have compromised histone-binding activity and suggest a relationship between this 
function of PHF20 and certain cancers. 
 
Figure 3.19 Cancer related PHD finger mutants decrease binding to H3K4me2 (A) 
Residues of the PHF20 PHD finger, found mutated in cancer, are shown as sticks in red and 
labeled. (B) Binding affinities of the cancer-relevant mutants of the PHF20 PHD finger for 
H3K4me2 relative to the binding affinity of the WT PHD finger as measured by NMR. (C) 
Overlays of 1H,15N HSQC spectra of the cancer-relevant mutants of the PHF20 PHD finger 
collected upon titration with the H3K4me2 peptide. 
 
3.5.2     Mutations in the PHD finger decrease binding to H3K4me2 
Substitution of residues in the aromatic dimethyllysine-binding pocket of the PHF20 PHD 
finger, including W675 to an alanine and F665 to a lysine, led to protein misfolding, pointing 
to the importance of these aromatic residues for structural stability of the PHD finger (Figure 
3.18C). Mutation of E662 to a lysine resulted in a folded, soluble, and stable protein, but 
completely abrogated interaction with both H3K4me2 and H3K4me3, allowing us to utilize 
this point mutation in characterizing the functional significance of the PHD-H3K4me2 
interaction in full-length PHF20 in vivo (Figures 3.18C and 3.20). 
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Figure 3.20 Overlays of 1H,15N HSQC spectra of the PHF20 PHD fingers E662K mutant 
collected upon titration with the indicated peptides.  
Then we used PHD E662K point mutant to do histone peptides pull-down. The results 
showed that E662K mutation abolished the binding between PHF20 PHD finger and 
H3K4me2 (Figure 3.21). 
 
Figure 3.21 PHF20 PHD fingers E662K mutant abolished the binding to H3K4me2. 
Western blot analysis of the peptide pulldown analysis using the WT PHF20 PHD finger and 
E662K mutant. 
 
3.6       Binding of the PHF20 PHD finger to H3K4me2 is required 
for MOF-dependent H4K16 acetylation and transcriptional 
regulation 
3.6.1     H4K16ac abundance is relative to the PHF20 level in lung 
adenocarcinoma cell lines 
PHF20 is a core subunit of the MOF-NSL lysine acetyltransferase complex, which is 
responsible for acetylating histone H4 at lysine 16 (H4K16) [49, 80]. Previous study reported 
that loss of acetylation at Lys16 of histone H4 is a common hallmark of human cancer [66].  
In order to study the correlation between PHF20 and H4K16ac level, we compared the level 
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of H4K16Ac as well as PHF20 level in normal cells to that in lung adenocarcinoma cancer 
cell lines. Surprisingly, our results showed that the lung adenocarcima cell lines have high 
level of H4K16ac, which was positive correlated with the PHF20 level (Figure 3.22). 
 
Figure 3.22 H4K16ac abundance is positive correlated with the PHF20 level in lung 
adenocarcinoma cell lines. Western blot analysis of H4K16ac abundance in the indicated 
lung adenocarcinoma cell lines and control immortalized normal cells. Histone H3 was used 
as a loading control.  
3.6.2     PHF20 depletion reduces the H4K16ac levels in promoters of target 
genes 
Because PHF20 has been implicated in transcription [47, 56, 57], we explored whether the 
histone-binding activity of the PHD finger is necessary for PHF20/MOF-dependent gene 
expression.  
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Figure 3.23 PHF20 depletion reduced the H4K16ac levels in promoters of target genes. 
(A) qRT-PCR analysis of H4K16ac ChIP on gene promoters in control (shNT) and PHF20 
KD (shPHF20) cells. (B) qRT-PCR analysis of total H3 ChIP on promoters of the indicated 
genes in cells as in (A). (C) qRT-PCR analysis of H3K4me2 ChIP on promoters and gene 
bodies of the indicated genes in H1792 cells. Error bars represent SEM of three biological 
replicates. 
Firstly, we performed the chromatin immunoprecipitation (ChIP) analysis to detect the 
H4K16ac occupancy on PHF20 up-regulated genes, and the results revealed a substantial 
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drop in H4K16ac levels in promoters of these genes, whereas the total H3 levels remained 
unchanged (Figures 3.23A and 3.23B). Notably, all the genes tested have strong H3K4me2 
levels on their promoters (Figure 3.23C). These findings suggest that PHF20 regulates gene 
expression likely through MOF-mediated H4K16ac. 
 
3.6.3     Binding of the PHF20 PHD finger to H3K4me2 is required for 
H4K16 acetylation. 
To characterize the role of the PHD finger in this regulation, we designed a reconstitution 
system in which shRNA-resistant WT PHF20 or E662K mutant, impaired in binding to 
H3K4me2, was re-introduced into the shPHF20 cells. As shown in Figure 3.24, knockdown 
of PHF20 led to reduced H4K16ac levels; importantly, WT PHF20, but not the E662K 
mutant, rescued the global reduction of H4K16ac levels.  
 
Figure 3.24 Western blot analysis of PHF20 and H4K16ac levels in control (shNT), 
PHF20 KD (shPHF20), and KD cells rescued with the WT PHF20 or E662K mutant. 
Total H4 and actin were used as loading controls. The density of H4K16ac bands was 
quantified using ImageJ. 
This was further substantiated by measuring H4K16ac levels in the promoters of PHF20 
target genes. PHF20 knockdown resulted in decreased H4K16ac levels, which were fully 
restored by WT PHF20, but were not restored by the E662K mutant (Figure 3.25).  
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Figure 3.25 qRT-PCR analysis of H4K16ac ChIP on promoters of the indicated genes in 
control (shNT), PHF20 KD (shPHF20) and KD cells rescued with the WT PHF20 or 
E662K mutant. Error bars represent s.e.m. of 3 biological replicates. **p values< 0.01. 
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3.6.4     Binding of the PHF20 PHD finger to H3K4me2 is required for gene 
transcription 
 
Figure 3.26 qRT-PCR analysis of gene expression in control (shNT), PHF20 KD 
(shPHF20) and KD cells rescued with the WT PHF20 or E662K mutant. Error bars 
represent s.e.m. of 3 biological replicates. **p values< 0.01. 
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Subsequently, WT PHF20 rescued the defects in target gene expression of the PHF20 KD 
H1792 cells, whereas the PHD finger mutant E662K, which is incapable of binding to 
H3K4me2, failed to do so (Figure 3.26) 
Collectively, these results suggest that the H3K4me2-binding function of the PHD finger 
is essential for PHF20-dependent histone acetylation and target gene activation. 
 
3.7      PHD finger is required for the biological function of PHF20 
3.7.1     PHF20 PHD finger is required for cell proliferation 
Since shRNA-resistant WT PHF20 but not PHD finger mutant can restore cell cycle related 
genes expression in PHF20-depleted cells, we expected that WT PHF20 can rescue the cell 
growth in PHF20-depleted genes. The cell proliferation assay showed that WT PHF20 
rescued the defects in cell proliferation of the PHF20 KD H1792 cells, whereas the PHD 
finger mutant E662K partly rescued.  
 
Figure 3.27 Cell proliferation assays of cells as in in control (shNT), PHF20 KD 
(shPHF20), and KD cells rescued with the WT PHF20 or E662K mutant.   
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3.7.2     PHF20 PHD finger is required for colony formation 
In accord with the resuts of the cell proliferation assay, the colony formation assay showed 
that WT PHF20 rescued the defects in colony formation of the PHF20-depleted H1792 cells, 
whereas the PHD finger mutant E662K failed to do so.  
 
Figure 3.28 Colony formation assays of cells as in control (shNT), PHF20 KD 
(shPHF20), and KD cells rescued with the WT PHF20 or E662K mutant. Representative 
crystal-violet-stained cells are shown in (A), and quantification of six replicates is shown in 
(B). 
Taken together, these results indicate that PHD finger is essential for PHF20-dependent 
cancer cell growth and survival. 
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4        DISCUSSION 
4.1      PHF20 PHD finger represents an example of a native reader 
capable of reading H3K4me2 
The plant homeodomain (PHD) finger is one of the largest families of epigenetic reader 
domains present in chromatin-related proteins, which are involved in the regulation of 
chromatin structure and dynamics [81]. The PHD finger is a small protein domain of ~65-
residue cysteine-rich sequence, which binds two zinc ions in a cross-braced topology. The 
PHD finger is an evolutionarily conserved module and is present either as a single module or 
in multiple copies [68].  
In the past few years, a wide array of PHD finger ligands have been identified. PHD fingers 
can mainly recognize different post-translational modifications (PTMs) on the H3 tail, 
including trimethylation of K4, trimethylation of K9, acetylation of K14 as well as 
unmodified histone H3 [41, 69, 70, 82-94]. The original discovery of their role in gene 
transcription is attributed to the recognition of trimethylated lysine 4 of histone H3 
(H3K4me3) [41, 42, 69, 70]. The PHD fingers of numerous proteins have been shown to bind 
H3K4me3 with high specificity and affinity. These readers of H3K4me3 together comprise 
one of the well-established subsets of PHD fingers. In 2007, the PHD fingers of BHC80 and 
DNMT3L were characterized that recognize unmodified histone H3 tail [93, 94], which 
represented the second major subset of PHD fingers. A smaller number of PHD fingers 
displays specificity for trimethylated lysine 9 of histone H3 (H3K9me3) [87-92]. The double 
PHD finger (DPF) domain of  DPF3b, MORF and MOZ select for acetylated histone H3 at 
lysine 14 (H3K14ac) [82-86]. 
In addition to trimethylated histone H3, the PHD finger can recognize dimethylated histone 
H3 at lysine 4 (H3K4me2), which is exemplified by the PHD finger of Pygo [77]. Pygo and 
BCL9 contribute to efficient β-catenin-mediated transcription in Wnt-stimulated mammalian 
cells [95, 96]. BCL9 proteins function as adaptors between Pygo and β-catenin, by binding to 
the PHD finger in the C terminus of Pygo through their homology domain 1 (HD1), and to 
the Armadillo repeat domain of β-catenin through their homology domain 2 (HD2) [97, 98]. 
Efficient methylated histone binding of Pygo PHD finger requires BCL9 HD1 association. 
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The PHD finger from human Pygo1 binds to H3K4me3 and H3K4me2 with similar high 
affinities (Kd, 2.5 and 2.4 µM, respectively).  After binding to the HD1 domain of BCL9, the 
human PHD-HD1 complex showed higher affinity to H3K4me3 and H3K4me2 (Kd, 1.2 and 
0.9 µM, respectively) [77]. The PHD finger of Pygo is the only one reported to bind to 
H3K4me2. In this study, we utilized biochemical and structural analyses to identify that the 
PHD finger of PHF20 specifically binds to H3K4me2, which represents an example of a 
native reader that selects for this modification. 
4.2     Functional link between Tudor2 and PHD of PHF20 
The PHD fingers are frequently found adjacent to other chromatin-binding modules, such as 
bromodomain [99, 100], tudor domains [40, 101], chromodomains [89] and other PHD 
fingers [82, 85], which aid combinatorial, multivalent readout of histone tails. The interplay 
between multiple readers and the DNA-binding domains creates an intricate network of 
contacts with nucleosomes and adds another layer of complexity to the chromatin-targeting 
mechanisms.  
Along with the PHD finger, PHF20 contains another methyllysine reader, the tandem Tudor 
domains, in which Tudor2 recognizes dimethyllysine substrates, such as p53K370me2 and 
p53K382me2 [40]. To determine whether Tudor2 competes with the PHD finger for the same 
posttranslational modification (PTM), we generated 15N-labeled Tudor2 and examined its 
interactions with H3K4me2 and p53K382me2 by 1H,15N HSQC. Substantial CSPs in PHF20 
Tudor2 were observed upon addition of the p53K382me2 peptide, and in agreement with 
previous reports, Kd for this interaction was found to be ∼100 μM (Figures 4.1A and 4.1C). 
In contrast, H3K4me2 peptide induced small CSPs in Tudor2 and was bound much weaker, 
with affinity of ∼1 mM. To test whether the PHD finger can compete with Tudor2 for 
binding to dimethylated p53, we next titrated the p52K382me2 peptide into the 15N-labeled 
PHD finger (Figure 4.1B). Lack of any CSPs in the spectrum demonstrated that the PHF20 
PHD finger does not recognize methylated p53. Despite some similarities in the amino acid 
(aa) sequences of dimethylated H3K4 and p53 (Tudor2 associates with p53K370me2 and 
p53K382me2 almost equally well), superimposition of the H3K4me2 peptide with the 
p53K370me2 peptide bound to Tudor2 provides a possible explanation for the inability of 
Tudor2 to recognize H3K4me2 (Figure 4.1D). Most likely, the positively charged N terminus 
of H3A1 and the side chain of H3R2 would be repelled from the positively charged surface 
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of Tudor2, where p53S367 and p53H368 are bound, and the neutral H3Q5-T6 sequence lacks 
the capacity to electrostatically interact with the negatively charged surface of Tudor2, where 
p53K372 and p53K373 are bound. In contrast, the absence of the AR sequence N-terminal to 
dimethyllysine likely precludes binding of the PHF20 PHD finger to dimethylated p53. These 
results demonstrate that, although both reader domains in PHF20 exhibit preference for 
dimethyllysine species, their functions do not overlap. 
 
Figure 4.1. Functional Coupling between Tudor2 and PHD finger of PHF20. (A and B) 
Superimposed 1H,15N HSQC spectra of the Tudor2 and PHD finger domains of PHF20 
collected upon titration with the indicated peptides. Spectra are color coded according to the 
protein:peptide molar ratio (inset). (C) Binding affinities of PHD and Tudor2 and alignment 
of the p53 and H3 sequences. Basic residues are in blue. (D) The electrostatic surface 
potential of the PHF20 Tudor2 domain bound to the p53K370me2 peptide is shown 
(PDB2LDM). Blue and red colors represent positive and negative charges, respectively. The 
p53K370me2 peptide (magenta) is manually superimposed with the histone H3K4me2 
peptide (green) derived from the PHF20 PHD-H3K4me2 complex. 
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Besides being a subunit of NSL, MOF is present in another evolutionarily conserved HAT 
complex, MSL [51, 53, 102]. Although both NSL and MSL complexes efficiently acetylate 
H4K16, only NSL is able to acetylate non-histone proteins, including p53 [50, 51]. Because 
the NSL-MOF complex, but not the MSL-MOF complex, contains the PHF20 subunit whose 
Tudor2 binds to dimethylated p53 [40], it is tempting to suggest that PHF20 might have a 
role in promoting p53 acetylation by MOF (Figure 4.2). Another possibility is that the 
distinctly different dimethyllysine-binding activities of Tudor2 and PHD in PHF20 tether or 
stabilize p53 at the genomic sites enriched in H3K4me2. It will be interesting in future 
studies to explore whether this functional coupling involving the two PHF20 readers exists. It 
is also essential to establish the role of PHF20 in regulating MOF activity on p53 as well as 
in p53-mediated DNA damage response, cell cycle regulation, and apoptosis. 
 
4.3    PHF20 links H3K4 methylation and H4K16 acetylation, 
interpreting the language of histone 
Post-translational modifications on histones act singly and in combination to form a language 
or 'code' that is read by specialized proteins, which in turn recruit additional epigenetic 
regulators to modulate chromatin dynamics [103, 104]. The dynamic nature of chromatin and 
its myriad modifications play a crucial role in transcriptional regulation [105]. In the current 
study, we found that recognition of H3K4me2 by PHF20 PHD finger is required for histone 
acetylation and accumulation of PHF20 target genes. We propose that H3K4me2 recruits the 
PHF20/MOF complex, which subsequently catalyzes acetylation of histone 4 at lysine 16 
(H4K16ac), leading to chromatin decondensation and transcriptional activation.  
Both histone marks, H4K16ac and H3K4me2, are vital epigenetic PTMs linked to 
transcriptional regulation. Accumulating evidence suggests that these modifications and the 
enzymatic complexes that produce them, such as MOF-NSL and MLL1, function in a highly 
cooperative manner [52, 53]. Although the mechanism underlying this close correlation is 
poorly understood, it has been suggested that WDR5, a component of both MOF-NSL and 
MLL1 complexes, plays a role [52, 102]. Structural analysis of the WD40 domain of WDR5, 
however, reveals that this protein associates with the H3 N terminus regardless of the 
methylation state of H3K4 [106-108], leaving the question of its possible role in functional 
cooperation of the enzymatic activities of the two complexes open. In this study, we 
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identified a relationship between the H4K16ac- and H3K4me-generating complexes. We 
show that the PHD finger of PHF20, a core subunit of the MOF-NSL HAT complex 
responsible for writing H4K16ac, recognizes H3K4me2, a mark generated by the MLL1 
methyltransferase complex [109] (Figure 4.2). Binding of the PHD finger to H3K4me2 is 
required for PHF20-dependent histone acetylation, occupancy of PHF20 at target genes, and 
transcriptional activation of these genes. Our results indicate that PHF20 links MOF to 
H3K4me2-mediated cellular processes and suggest a model for rapid propagation of 
H4K16ac-enriched open chromatin.  
Because the MOF complex contains several subunits capable of binding to histones or DNA, 
including H3-recognizing WDR5 and putative DNA-binding domains in the NSL2 subunit, 
we expect that multiple contacts contribute and/or fine-tune the MOF recruitment to specific 
chromatin loci. Further studies are needed to investigate the interplay of the histone- and 
DNA-binding activities within the MOF complex. 
 
Figure 4.2 A model depicting a potential role of PHF20 readers in linking H3K4 
methylation with H4K16 acetylation as well as p53 methylation and acetylation.  
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SUMMARY 
Lung cancer is the most common cancer and the leading cause of cancer death worldwide. 
Most lung cancers are diagnosed at an advanced stage, where the prognosis is poor and the 
therapeutic options are limited. In order to develop more effective novel strategies in lung 
cancer diagnosis and treatment, the underlying molecular and cellular mechanisms of lung 
cancer remains to be explored.  
PHF20 was originally identified as a target of autoantibodies in patients suffering from 
glioblastoma. Then abnormal expression of PHF20 in various cancers including non-small 
cell lung cancer, small cell lung cancer was reported, indicating that PHF20 might be tumor-
associated factor. However, little is known about the function of PHF20 in cancer 
development. PHF20 is a core component of the lysine acetyltransferase complex MOF-NSL 
that generates the major epigenetic mark H4K16ac and is essential for transcriptional 
regulation and DNA repair. As a multi-domain protein, PHF20 contains several domains 
including two Tudor domains and a PHD finger, which are putative methylation reader 
modules. However, the role of PHF20 in the MOF complex remains elusive. 
In this study, we use non-small cell lung cancer as a model to investigate the epigenetic role 
of PHF20 in cancer development. The abundant expression of PHF20 in lung 
adenocarcinoma cell lines was validated. Depletion of PHF20 mRNA in lung 
adenocarcinoma inhibits cell growth and colony formation.  RNA sequencing (RNA-seq) 
analysis showed that PHF20 affected genes are implicated in cell cycle and DNA replication. 
Biochemical and structural analyses showed that the PHD finger of PHF20 recognizes 
dimethylated lysine 4 of histone H3 (H3K4me2) and represents an example of a native reader 
that selects for this modification. Binding of the PHD finger to H3K4me2 is required for 
histone acetylation, accumulation of PHF20 at target genes, and transcriptional activation. 
Together, our findings establish a unique PHF20-mediated link between MOF histone 
acetyltransferase and H3K4me2. We propose that PHF20 recognizes H3K4me2 through its 
PHD finger and recruits the MOF complex to the chromatin, which subsequently catalyzes 
acetylation of histone 4 at lysine 16 (H4K16ac), leading to chromatin decondensation and 
transcriptional activation. 
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ZUSAMMENFASSUNG 
Lungenkrebs ist die häufigste Krebsart mit der höchsten Mortaliät weltweit. Die meisten 
Lungenkrebsarten werden erst in einem fortgeschrittenen Stadium der Erkrankung  
diagnostiziert, wo die Prognosen ungünstig  und die therapeutischen Optionen begrenzt sind. 
Um neue effektivere  Strategien bei der Lungenkrebsdiagnose und -behandlung zu 
entwickeln, müssen die zugrunde liegenden molekularen und zellulären Mechanismen des 
Lungenkrebses weiter aufgeklärt  werden. 
PHF20 wurde ursprünglich als ein Target für Autoantikörper von Patienten mit einem 
Glioblastom identifiziert. Die abnormale Expression von PHF20 in verschiedenen 
Krebsarten, einschließlich im kleinzelligen und nicht-kleinzelligen Lungenkrebs, weist auf 
eine potentielle Rolle dieses Proteins als Tumor-assoziierter Faktor hin.  Allerdings ist wenig 
über die Funktion von PHF20 in der Tumorentwicklung bekannt. PHF20 ist eine 
Kernkomponente des MOF-NSL Histon-Acetyltransferase-Komplexes, das für die wichtige 
epigenetische Markierung H4K16ac, und für die transkriptionelle Regulation und DNA-
Reparatur essentiell ist. Als multidomänales Protein enthält PHF20 zwei Tudor-Domänen 
und eine PHD-Finger-Domäne, die vermutlich in der Methylierungserkennung involviert 
sind. Jedoch ist die Rolle von PHF20 im MOF-Komplex noch nicht vollständig geklärt.   
In dieser Studie verwendeten wir nicht-kleinzelligen Lungenkrebs als Modell, um die 
epigenetische Rolle von PHF20 in der Tumorentwicklung zu untersuchen. Die erhöhte 
Expression von PHF20 wurde in Lungen-Adenokarzinom-Zelllinien validiert. Eine Depletion 
von PHF20-mRNA in diesen Zelllinien führte zu einer Hemmung des Zellwachstums und 
der Koloniebildung. Expressionsanalysen durch quantitative RNA-Sequenzierung (RNA-seq) 
offenbarten, dass PHF20 in der Regulation von Genen des Zellzyklus und der DNA-
Replikation involviert ist. Biochemische und strukturelle Analysen zeigten, dass der PHD-
Finger von PHF20 spezifisch am dimethylierten Lysinrest in Position 4 am N-terminalen 
Ende im Histon H3 (H3K4me2) bindet, was zugleich ein Beispiel für die native 
Funktionsweise dieser Domäne ist. Die Bindung des PHD-Fingers an H3K4me2 ist für die 
Histon-Acetylierung sowie für die Akkumulation von PHF20 an Zielgenen und die 
Transkriptionsaktivierung erforderlich. Zusammenfassend lässt sich feststellen, dass unsere 
Erkenntnisse eine einzigartige PHF20-vermittelte Verbindung zwischen der MOF-Histon-
Acetyltransferase (HAT) und H3K4me2 darstellen. Wir nehmen an, dass PHF20 H3K4me2 
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durch einen PHD-Finger erkennt und den MOF-Komplex zum Chromatin rekrutiert, welcher 
anschließend die Acetylierung von Histon 4 am Lysin 16 (H4K16ac) katalysiert. Dies führt 
zu einer Chromatindekondensation und Aktivierung der Transkription. 
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ABBREVIATION 
PHF20, plant homeodomain finger protein 20 
GLEA 2, glioma-expressed antigen 2 
PHD, plant homeodomain 
MOF, male absent on the first 
NSL, non-specific lethal 
H3K4me2, dimethylated lysine 4 of histone H3 
HAT, histone acetyltransferase 
SCLC, small cell lung cancer  
NSCLC, non-small cell lung cancer 
SqCC, squamous cell carcinoma 
AdC, adenocarcinoma 
HCA58, hepatocellular carcinoma associated antigen 58  
ATM, ataxia telangiectasia mutated  
WDR5, WD repeat domain 5  
MLL1, mixed-lineage leukemia 1 
IPSCs, induced pluripotent stem cells  
PBS, phosphate buffered saline 
FBS, fetal bovine serum 
PMSF, phenylmethanesulfonyl fluoride 
SDS, sodium dodecyl sulfate 
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DTT, 1,4-dithio-DL-threitol 
APS, ammonium persulfate  
IPTG, isopropyl b-D-1-thiogalactopyranoside   
NMR, nuclear magnetic resonance 
GST, glutathione S-transferase 
HSQC, 1H,15N heteronuclear single quantum coherence  
CSPs, chemical shift perturbations  
ING2, inhibitor of growth, member 2 
ChIP, chromatin immunoprecipitation  
RIPA, radio immunoprecipitation assay 
DNA, desoxyribonucleic acid 
RNA, ribonucleic acid 
shRNA, short hairpin RNA 
RNA-seq, RNA sequencing  
qRT-PCR, real time quantitative reverse transcriptase polymerase chain reaction 
IPA, Ingenuity Pathway Analysis 
KD, knockdown 
TAF3, TATA-Box Binding Protein Associated Factor 3 
BPTF, bromodomain PHD finger transcription factor 
WT, wild-type 
PTM, post translational modification  
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